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Abstract 
 
Integrated Microfluidic Molecular Diagnostics for Point-of-Care 
 
By 
 
Erh-Chia Yeh 
 
Joint Doctor of Philosophy in Bioengineering with 
 
University of California, San Francisco 
 
University of California, Berkeley 
 
Professor Luke P. Lee, Chair 
 
 
Ideal point-of-care medical diagnostic devices are low cost assays capable of 
performing quantitative on-site rapid testing with high sensitivity and minimal manual 
steps.  
Current mainstream assays have several key limitations. Take, for instance, the 
common lateral flow assay—e.g. the pregnancy dipstick test. Such assays produce 
rapid results at low cost; however, they are mostly qualitative tests yielding only 
positive/negative results rather than quantitative figures. Other standard immunosorbant 
assays such as ELISA yield quantitative results but require several hours and extensive 
manual operation. At the other end of the spectrum, nucleic acid amplification 
techniques such as quantitative real-time PCR can deliver much higher sensitivity and 
selectivity. Unfortunately, these require costly equipment and several sample 
preparation steps.  
In this thesis, an integrated low-cost microfluidic chip and peripheral technologies for 
quantitative molecular diagnostics is described. These technical advances are designed 
to address the prevailing dilemmas described above. 
Researchers have developed and integrated several key components with 
microfluidic lab-on-chip miniaturization technology. In line with cutting-edge technology, 
a novel reagent patterning method, termed “digital micro-patterning”, was developed. A 
very simple method, it can be adopted at low-resource laboratory settings with 
mainstream equipment. Digital micro-patterning is unique in the sense that it can 
digitally pattern and concentrate reagents into highly defined micro-patterns. As a proof 
of concept, it was possible to pattern isothermal amplification reagents in hundreds of 
microwells and run amplification reactions in these wells. 
Next, a next-generation passive microfluidic pumping technology, termed the 
“vacuum battery system”, has been developed. This system allows for precise passive 
microfluidic pumping without external pumps, controls, or power sources for up to 
several hours. It does not require opaque fibers as in capillary systems (e.g. lateral flow 
assays), thus rendering this pumping method very attractive for optical detection 
platforms. The vacuum battery system is also significantly more robust compared to 
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previous degas pumping techniques. Due to its portability, excellent optical properties, 
low cost, and the ability for complete integration with microfluidics, this platform 
technology opens exciting new opportunities to create a nouveau generation of 
standalone microfluidic chips readily operable in field settings. 
Additionally, a microfluidic sample preparation technology termed “digital plasma 
separation” has been developed. This technology uses parallel micro-cliff-like structures 
and gravity sedimentation to simultaneously separate plasma and compartmentalize 
samples into hundreds of micro-wells within minutes. Such sample preparation method 
enables isothermal digital nucleic acid amplification in one step.  
As a proof of concept, these technologies were integrated into a single microfluidic 
chip, termed the Integrated Molecular Diagnostics Chip (iMDx). This chip is capable of 
performing one-step quantitative nucleic acid detection directly from human whole blood 
samples (10~105 copies/ µl in 30 minutes). One low-cost disposable chip (~ $10) is 
designed to integrate and automate sample preparation, quantitative isothermal digital 
nucleic acid detection, and next generation autonomous microfluidic pumping. This 
portable integrated chip can acquire template concentration data similar to bench top 
real-time PCR machines. As the latter can cost three or more orders ($30~80k), this 
chip opens exciting opportunities for rapid point-of-care diagnostics in resource-low 
settings. 
Finally, in summarizing these cutting-edge methods, a blueprint for next-generation 
technical development plans is laid out. The key areas of focus are downstream 
microfluidic integration for advanced functionality such as protein and nucleic acid 
multiplexed detection on a single chip, telemedicine, mass production, and clinical 
studies in field settings.  
Ultimately, the implication of the research in this dissertation is that these platform 
technologies can be adopted into future medical diagnostic devices to enable rapid on-
site quantitative molecular level detection at significantly lower costs. Both the system-
level design rationale and component technologies developed herein provide promising 
building blocks for future point-of-care diagnostic assays.  
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Chapter 1. Introduction to Integrated Molecular Diagnostic 
Systems  
 
Current standard quantitative molecular diagnostic tests, such as quantitative 
nucleic acid detection, are often done in centralized laboratories with costly bench 
top equipment. This kind of testing is challenging for resource-poor rural areas, 
which often lack infrastructure, funding, and trained personnel. Unfortunately, areas 
hardest hit with pandemic diseases are often developing countries with the least 
medical resources. For example, Figure 1 shows that the highest prevalence of HIV 
occurs in developing countries, with more than 60% of infections taking place in sub-
Saharan Africa, where less medical infrastructure is available. 
Point-of-care diagnostic devices can be brought to the field for on-site testing. They 
are typically low-cost, portable and can be operated with few simple steps. Point-of-
care diagnostic devices are designed to alleviate the need for patients to travel to 
centralized hospitals. They are designed to be brought to the patients instead. 
Current common examples of widespread commercially available point-of-care 
devices include the pregnancy test and glucose testing meters. However, these 
systems are limited in several ways. Pregnancy tests are not quantitative and 
glucose meters have sensitivities too poor (~mg/mL) to adopt for protein detection. 
There is a need to develop low-cost assays that can quantitatively detect nucleic 
acid molecules down to the molecular level for next-generation diagnostic systems.  
In this dissertation, some of the developed integrated microfluidic components and 
Figure 1 HIV prevalence is highest in developing countries, however these 
countries often have less medical resource such as trained personal, centralized 
labs, and income per capita. Numbers denote the number to infected patients in 
each continent in millions. (ref: UNAIDS)  
 2 
systems that provide a comprehensive solution for quantitative molecular detection 
are presented. It is important to consider system integration early on, otherwise 
during later integration stages of assay development one may realize that intrinsic 
limitations pose major difficulties from incompatibilities among system components. 
With this in mind, it is crucial to first thoroughly review current state-of-art 
technologies in order to identify strength and weaknesses in each approach. Then 
will it be possible to build compatible systems that can be seamlessly integrated 
together.  
The goal of chapter 1 of this dissertation is to give a comprehensive review and 
comparison of current state-of-art technologies relevant to the design of next 
generation point-of-care diagnostic devices. In this chapter, the majority of 
references stem from publications published after 2010. This was done in order to 
highlight the most recent advances in this field. Older references are sometimes 
added when they are of particular importance. In Chapter 1, first the key 
requirements necessary for next generation point-of-care diagnostic platforms is 
discussed. Then, individual components of each step of assay design will be 
presented 
In later chapters of this dissertation, research results from the development of the 
Integrated Molecular Diagnostic Chip (iMDx) will be presented. Specific advances in 
microfluidic sample preparation, and next generation power-free passive microfluidic 
pumping will be discussed. A prototype of the iMDx chip that can perform 
quantitative nucleic acid detection directly from human blood samples in 30 minutes 
is shown. On-chip micro-patterning of reagents will also be detailed. Finally, 
conclusions and vision for future research and development plans is laid out.  
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1.1 Key requirements for next generation point-of-care diagnostic 
platforms 
 
Current standards for antigen and nucleic acid detection 
 The current common standards for assays and their respective strengths and 
weaknesses are shown in Figure 2. Lateral flow assays1 generally use antibodies to 
capture antigens in a fibrous wicking pad, and then latex beads or gold nanoparticles 
are used as signal enhancers for naked eye readout. The pregnancy dipstick test or 
HIV oral swab test are common examples of commercially available qualitative 
lateral flow assay tests. Nucleic acid hybridization assays2–7 have also been 
developed for amplification result end-point detection with lateral flow assays. These 
assays can be done in 10~20 minutes. Though rapid and economical, these kinds of 
assays are typically not quantitative. Only a yes/no answer is given for readout. 
However, lateral flow assays are widely used in the field because of their simplicity.  
 
 Enzyme linked immunosorbant assays (ELISA) have a similar antibody-antigen 
ligand binding process, however ELISA’s are prepared on clear polystyrene or 
polycarbonate plates, and ELISA uses enzymes such as horse radish peroxidase or 
alkaline phosphatase to amplify the readout signal by causing a colour change in the 
substrate. Due to the clear optics and enzymatic signal enhancement, ELISA assays 
Figure 2 Examples of common diagnostic assay standards. (ref: pictures from 
Oraquick, Wikipedia (Jeffrey M. Vinocur), and Bio-Rad)  
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are quantitative. However because ELISA needs multiple washes, several hours of 
assay time, and special plate reading machines, ELISA assays are difficult to 
perform in the field.  
 
 The current standard for nucleic acid detection is based on Polymerase Chain 
Reaction (PCR). This is commonly done on quantitative PCR machines. PCR is the 
most sensitive molecular assay, it is possible to detect down to one molecule per 
reaction. However, the main disadvantages are the high cost, the need of technical 
expertise, and long assay time. The high cost is because quantitative PCR machines 
need a heat cycling apparatus, computer, and a fluorescent detection shuttle that 
scans the microplate wells every few seconds. These machines can easily cost up to 
$40~80k, and they are usually bulky bench top machines that are not portable. In 
addition, they require external power sources, which are often taken for granted in 
developed countries, but may not be available or stable in rural areas of the world. 
Also, sample preparation is needed for PCR assays as nucleic acid needs to be 
purified from complex samples in order to avoid inhibition of the polymerase 
enzymes in PCR. Sample preparation is manually intensive and also as well as the 
setup of PCR too. These limitations render PCR testing to be performed 
predominately at centralized lab facilities. However, this may be a hindrance for 
those who have to travel far from rural villages to be tested. Finally, the total assay 
time is typically 1~3 hours so patients would often have to wait for results until the 
clinic contacts them later, which can be several days. This may cause additional 
problems because contact may be difficult once the patient returns to distant rural 
villages.    
 
 
Standards for the next generation of point-of-care devices 
Table 1 Components of a Clinical Laboratory Improvement Amendments (CLIA) 
waiver application. (ref: FDA, CLIA waiver applications for manufacturers of in vivo 
devices, 0910-0598) 
 
CLIA wavier required demonstrations 
• Demonstrating the device to be simple to use. 
• Results of risk analysis including the identification of potential sources of 
error for your device.  
• Demonstrate insensitivity to variations of environmental and usage. 
• (1) Describe measures implemented to mitigate risk of errors, and (2) 
demonstrate ability of failure alert, fail-safe mechanisms, and other control 
measures to mitigate risk errors.  
• Demonstrate that the device has an insignificant risk of erroneous result in 
the hands of the intended user.  
• Proposed labeling with instructions for use consistent with a device that is 
“simple”. 
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 With the limitations of current systems laid out in the last section, there is a need to 
define what would be ideal assays for next generation point-of-care devices. 
Guidelines from the Food and Drug Administration is shown in Table 1, and Table 2. 
These guidelines are  examples of the desirable characteristics of future devices for 
point-of-care.  
Table 2 Definition of “simple” for CLIA waived devices. (ref: FDA, CLIA waiver 
applications for manufacturers of in vivo devices, 0910-0598) 
Simple tests should include these characteristics 
• Is a fully automated instrument or a unitized or self-contained test. 
• Uses direct unprocessed specimens, such as capillary blood (fingerstick), 
venous whole blood, nasal swabs, throat swabs, or urine. 
• Needs only basic, non-technique-dependent specimen manipulation, 
including any for decontamination. 
• Needs only basic, non-technique-dependent reagent manipulation, such as 
“mix reagent A and reagent B.” 
• Needs no operator intervention during the analysis steps. 
• Needs no technical or specialized training with respect to troubleshooting or 
interpretation of multiple or complex error codes. 
• Needs no electronic or mechanical maintenance beyond simple tasks, e.g., 
changing a battery or power cord. 
• Produces results that require no operator calibration, interpretation, or 
calculation. 
• Produces results that are easy to determine, such as ‘positive’ or ‘negative,’ 
a direct readout of numerical values, the clear presence or absence of a 
line, or obvious color gradations. 
• Provides instructions in the package insert for obtaining and shipping 
specimens for confirmation testing in cases where such testing is clinically 
advisable. 
• Has test performance comparable to a traceable reference method as 
demonstrated by studies in which intended operators perform the test. If a 
reference method is not available for a test you are proposing for waiver, 
please contact OIVD to discuss your proposed plan prior to submitting your 
application. 
• Contains a quick reference instruction sheet that is written at no higher than 
a 7th grade reading level. 
Should not include these characteristics 
• Sample manipulation is required to perform the assay. (For example, tests 
that use plasma or serum are not considered simple.) Sample manipulation 
includes processes such as centrifugation, complex mixing steps, or 
evaluation of the sample by the operator for conditions such as hemolysis 
or lipemia. 
• Measurement of an analyte could be affected by conditions such as sample 
turbidity or cell lysis. 
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 Table 1 shows the necessary components for the application of the Clinical 
Laboratory Improvement Amendments (CLIA) waiver defined by the FDA. All testing 
on human specimens for diagnostic, prevention, and treatment in lab facilities in the 
United States are regulated by the CLIA regulations set by FDA. A device that has 
obtained the CLIA waiver certificate is a device simple and robust enough that there 
will be low risk of error. For example, FDA approved home tests automatically 
qualifies for a CLIA wavier. In simple terms, companies that develop point-of-care 
devices generally wish to obtain a CLIA wavier, so they can prove that their device is 
simple and robust for point-of-care applications. More information can be found on 
FDA’s definition of “simple” in Table 2.  
 In summary, the CLIA guidelines are important to have in mind early on in the 
design phase of developing assays. The CLIA waiver guidelines should be the basic 
framework when one develops a diagnostic device. 
 
 
Design considerations for point-of-care molecular diagnostic systems 
 One of the first design considerations is to decide whether the assay platform will 
be fibre/paper8–15 based or microfluidic16–19 based. Fibre/paper systems are those 
found in lateral flow assays. Microfluidic based systems usually use a transparent 
polymer or elastomer (e.g. PC, PS, COC, PDMS) to make the devices. A 
 
Table 3 Comparison of platform technologies. 
 
 Advantages Disadvantages 
Paper
/fibre 
based  
Lower cost 
Ease of disposal (burning) 
High surface area 
Equipment-free pumping  
Proven in field  
 
 
Optically opaque 
Evaporation  
2D geometry 
No liquid storage 
Not ideal for PCR, ELISA 
Quantification more difficult 
Harder integration with electronics 
Difficult to integrate with 
microfluidics 
 
Microflui
dic 
based 
Optical clarity 
Higher sensitivity 
Microfluidic integration  
Low evaporation for PCR 
Higher consistency 
Easier integration with electronics 
Easier integration with mechanics 
Micro/nano scale fluidics 
Digital PCR, ELISA possible 
Liquid reagent storage 
Higher cost 
Pumping system needed 
Disposal problems 
Lower surface area 
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comparison of the relative advantages and disadvantages of the two systems is 
shown in Table 3. Considering the strengths of each platform, paper systems seem 
to be best suited for protein, chemistry, and post amplification nucleic acid amplicon 
verification assays. However, it is difficult to run paper-based systems for PCR 
amplification because evaporation can be a problem at elevated temperatures. The 
opaqueness of paper/fibre is also a major drawback for more sensitive and 
quantitative optical detection. On the other hand, microfluidic based methods have a 
lot of potential applications in quantitative detection, in particular nucleic acid 
amplification assays. This is because microfluidic platforms can be made with highly 
transparent polymers, so various types of optical detection techniques can be used 
on microfluidic platforms. For example, fluorescence, bright field, phase contrast, 
dark field, spectroscopy, and absorption can be done with a clear substrate. For this 
dissertation work, focus has been emphasized on developing microfluidic-based 
components due to these reasons.  
 The next step of design is to have a whole picture in mind of what is necessary for 
a complete integrated system. Figure 3 shows what technologies one would need to 
consider involved in each stage of the assay. It is important to set the outline early 
during the development, and ensure each individual component is fundamentally 
compatible with the entire system. This chapter will provide a detailed up-to-date 
review of the most recent developments of each of these components.  
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1.2 Sample preparation with plasma separation  
 
 If the input sample is human whole blood, blood cell removal is often 
necessary for down stream analysis because the blood cells can interfere with 
assays. For example, hemoglobin in red blood cells is a major polymerase inhibitor 
because of hemoglobin's chelating nature. 0.1% of blood in a reaction mix can cause 
a PCR reaction to fail. Also blood cells can interfere with optical readout because 
they scatter light and can be opaque when concentration is high. Table 4 is an 
example of several blood cell removal techniques commonly used. In addition, 
Kersaudy-Kerhoas22 et al., has done an excellent review on blood separation 
methods. Methods using the Zweifach-fung21 effect have a main microfluidic channel 
pumping at high speed, and small perpendicular side microfluidic channels pumping 
out of the side of the main channel; the blood cells are separated via inertial effects. 
The disadvantage of this type of separation is that precisely controlled external 
 Comparison of plasma separation methods 
Mechanism Centrifugation Microfluidic 
size 
exclusion f
iltration  
Zweifach-
Fung e
ffect AM 
Membrane s
ize exclusion 
filtration 
Microfluidic 
sedimentation  
Example Microfluidic ro
tating disk  
Microfluidic 
filters2120 
Integrated 
barcode 
chip2221 
www.amic.se 
 
Digital Plasm
a Separation 
External P
ower 
Requirements 
Electrical or 
mechanical 
power source 
required 
Controlled 
external 
pressure 
for flow 
propulsion 
is required. 
Controlled 
external 
pressure 
for flow 
propulsion 
is 
required. 
None None 
Manufacturing 
Precision 
Low High Low Low Low 
Cost Medium Medium Low Low Low 
Portability Low Low Low High High 
Separation 
Efficiency  
90% 20% 50% 20% >95 % 
Clogging Prob
lems 
No Yes No  Yes No 
Table 4 A comparison of plasma separation methods. 
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pumps are required. In the later chapters of this dissertation, work on the digital 
plasma separation platform, which is a microfluidic sedimentation based method will 
be presented. 
 
1.3 Next generation nucleic acid detection methods  
Table 5 A comparison of nucleic acid detection methods. 
Method Advantages Disadvantages 
Real-time 
PCR 
well established 
primers design straightforward 
no PCR reagent license issues 
quantitative 
higher equipment cost 
bulky machines 
need power source 
evaporation problems 
catastrophic bubble expansion 
Ultrafast 
PCR 
primers design straightforward 
no PCR reagent license issues 
rapid 
quantitative 
higher equipment cost 
bulky machines 
need power source 
evaporation problems 
catastrophic bubble expansion 
Isothermal 
amplificatio
n 
lower temperature 
possible without power source (heat packs) 
less evaporation and bubble problems 
rapid 
power-free possible 
simpler equipment 
still patent protected  
primer design more complex 
less literature 
higher reagent cost 
certain types need more than 2 primers 
DNA 
microarrays 
highly multiplexed 
broad detection  
ideal for novel pathogen detection 
lower sensitivity 
many washes and long assay time 
need special scanner for readout 
lower signal intensity 
Nucleic 
acid lateral 
flow assay 
quick readout 
naked-eye readout 
not quantitative 
limited multiplexing 
often needs off-chip amplification 
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A comparison table of nucleic acid detection technologies is shown in Table 5. 
Currently, the most dominant form of quantitative nucleic acid analysis is via real-
time PCR. Molecular level DNA/RNA template detection, template concentration 
identification, and melting curves are among the most commonly acquired data from 
real-time PCR. Another nucleic acid detection method- the DNA microarray23–25, is 
also used widely for the analysis of gene expression applications. On the other hand, 
more recent technologies are such as nucleic acid lateral flow assays and isothermal 
amplification technologies. Both microarray and nucleic acid lateral flow assays is 
base on the principle of DNA hybridization. In essence, the nucleic acid lateral flow 
assay is very similar to antibody based lateral flow assays, except that the 
biomolecule capture mechanism is DNA hybridization instead of antibody-antigen 
binding reactions. More recent technologies are such as the ultrafast PCR26–28 or 
isothermal amplification will be discussed in more detail in the following sections.  
 
Isothermal amplification methods 
 Isothermal amplification29–41 is one of the fastest growing technologies for 
applications in point-of-care settings. A comparison of isothermal amplification 
Table 6 Comparison of isothermal amplification technologies. (ref: David Boyle et 
al., Point-of-care nucleic acid testing for infectious diseases, 2011). 
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technologies can be found in Table 64242. Isothermal amplification is a new kind of 
nucleic acid amplification technology. Instead of using thermal cyclers to denature 
double stranded amplicons as in conventional PCR, isothermal amplification uses 
enzymatic activity to displace double stranded DNA, so no thermal cycling is 
required. This allows all amplifications to be carried at a constant temperature which 
is typically much lower than 95 °C, eliminating the need for costly thermal cycling 
equipment and allows for electricity-free heating alternative options. Various 
isothermal heating methods will be discussed in the next section. Also since reaction 
temperatures are lower, there are less evaporation problems and less chance of 
catastrophic air bubble expansion in microfluidic devices, making the design 
requirements easier for microfluidic chips. Another advantage of this kind of method 
is that reactions can often be extremely fast, for example, recombinase polymerase 
amplification43 (RPA) can amplify in 5~20 minutes, and NEAR technology can 
amplify as fast as 10 minutes. Also there are many cases showing higher robustness 
in complex samples than PCR. For example, in later chapters of this dissertation, it is 
shown that RPA can amplify directly from human blood plasma whereas PCR is 
completely inhibited.  
 Nevertheless, there are several limitations with isothermal amplification. For one, 
primer design is not as straightforward as conventional PCR, for example, loop 
mediated amplification44 (LAMP) uses up to six primers. Also, primer design 
algorithms may not be completely clear, and sometimes experimental optimization 
may be needed. Also, another potential limitation is that most of these isothermal 
techniques still have patent protection, and reagent costs may be higher than 
conventional PCR due to patent protection, though this problem will cease as 
patents expire in the next few years.    
 In recent years, RPA has started to see an explosion of research activity. RPA 
seems to be starting to replace the previous most popular LAMP technology. The 
reason for this adoption is because RPA is one of the fastest and robust isothermal 
technologies commercialized. Other types of isothermal amplification technologies 
often are not widely commercialized yet (except for LAMP, NASBA, and HDA).  RPA 
also is very robust and can amplify directly from blood plasma, stool samples, leaf 
extract, and urine. Though the primers still need to be experimentally optimized, 
there are a plethora of target pathogen primers being developed these years. Also, 
for point-of-care devices, usually only a few primers are needed on one chip, so 
there is no need to redevelop primers for each disease. One can simply select 
primer sequences from literature for specific diseases, and integrate that on-chip. 
For these reasons, there have been several new commercial examples that use RPA 
as a detection platform. The most common current commercial platform is 
performing tube based amplification, then running the reaction mix through a nucleic 
acid lateral flow assay for a yes/no qualitative readout. With these merits, isothermal 
technologies similar to RPA would likely be the key to change future development of 
point-of-care diagnostics.  
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1.4 Microfluidic pumping methods 
 
 There are two main types of fluidic pumping- active and passive systems. Table 
745 shows a list of examples of common active pumping techniques. Table 8 shows 
a comparison of common passive pumping systems with the vacuum battery system 
that is presented in this dissertation; a more comprehensive report on the vacuum 
battery system will be discussed in the later chapters of this dissertation.  
 Active46–54 pumping systems are systems that require external power and control 
sources. Active pumping includes surface acoustic waves, piezoelectric actuation, 
pneumatic valves, syringe pumps, and electroosmotic pumping, etc. In general, they 
have a higher degree of control and precision than passive systems. However, the 
high cost of active systems and the requirement for external pumps, pneumatic 
systems, power sources, control systems, makes active systems more difficult to 
adopt for low cost point-of-care diagnostic applications. 
 On the other hand, passive pumping systems are an attractive alternative for 
adoption in low cost point-of-care assays. One common example is fibre based 
capillary wicking; these are often seen in lateral flow assay tests such as the 
disposable pregnancy test. Paper based assays8,55,56 also use wicking fibrous 
material for pumping. Though simple, these systems are opaque and can interfere 
with optical detection. A second common type of capillary pumping is using fluid 
wicking into plastic sheets gaps that are hydrophillically treated, this is often seen in 
glucose test strips. More recently, more complex logic functions have been 
developed with capillary microfluidic structures. For example, sequential flow57 and 
programed circuits58 utilizing triggers and valves have been developed. Though 
these new developments hold lots of promise for more complex liquid handling, there 
are a few challenges that are intrinsic with capillary systems. For example, the 
wicking surface needs to be hydrophilic, while most plastics are hydrophobic, so 
special surface treatments are needed to lower the surface energy. Also, since  
Table 7 Common examples of microfluidic pumping. (ref: Pamela N. Nge, 
Chemical Reviews, 2013).  
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Active 
systems 
Capillary 
Loading 
Conventional 
degas flow µSIP 
Vacuum 
Battery 
System 
Examples 
syringe 
pumps, 
quake 
pumps 
pregnancy test 
strips 
SIMBAS59 
system 
Microfluidic 
Solution 
Isolated 
Pumping60 
this work 
Mechanism 
external 
power 
source 
wicking by 
capillary action 
degas through 
permeable 
materials 
degas 
through 
membrane 
void space 
stores 
vacuum 
and degas 
through 
lung like 
structures 
Portability difficult yes yes yes yes 
Cost high low low low low 
Optical 
properties NA 
fibers are 
opaque or 
cause 
autofluorescen
ce 
transparent transparent transparent 
Flow control excellent superior than degas 
flow has fast 
exponential 
decay 
depends on 
thumb 
pumping 
5 times 
longer 
decay time 
constant 
than degas 
flow 
Flow speed nl~ml/min µl~ml/min ~µl/min ~nl/min 
10 times 
faster than 
degas, also 
faster than 
µSIP. 
(nl~µl/min) 
Dead-end 
loading no no yes yes yes 
Loading 
volume not limited µl-ml nl-µl nl-µl nl-ml 
Operation 
time not limited secs~mins mins 
depends on 
thumb 
pumping 
hours 
Geometrical NA no deep height none none none 
Table 8 A comparison table of passive pumping technologies. Red highlights show 
disadvantages compared to the vacuum battery system.  
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constraints channels 
Surface 
treatment none 
need to be 
hydrophillic none none none 
Equipment/ 
power free no yes yes 
need thumb 
pressing none 
Constructio
n 
complex with 
peripherals simple simple 
extra valve 
structure 
and thumb 
pump layer 
needed. 
Simple two 
layer 
fabrication 
 
 
capillary force depends on geometry, deep channel designs are difficult to achieve in 
capillary pumping. Another problem is that capillary pumping does not remove 
trapped bubbles, which can become a problem if any heating steps such as thermal 
cycling in PCR are done, as these bubbles may expand and push out liquid in an 
uncontrollable manner.    
 An alternative kind of passive pumping is called degas pumping61–76. These degas 
pumping systems use PDMS degassing to create gentle vacuums to drive flow. 
However, degas loading is not consistent and decays very rapidly. This dissertation 
presents a unique system called the vacuum battery system, which uses large voids 
to store vacuum, and release the vacuum potential in a controlled manner. The main 
advantage of the vacuum battery system over conventional degas pumping is that 
the vacuum battery system has much better stability and consistency, loads faster, 
operates for longer time, and can be easily tuned. In addition, the vacuum battery 
system can also remove air bubbles, perform dead-end loading, and has excellent 
optical transparency. The vacuum battery system will be discussed in more detail in 
the following chapters of this dissertation. A patent application for the vacuum battery 
system has been submitted and is current under review.   
 
 
 
 
 
1.5 Reagent patterning methods 
  
 For reagent patterning, several methods commonly used are shown in Figure 477. 
The main considerations of patterning systems are the cost of the system and the 
volume size and footprint needed for each application. The reagent to be patterned 
also is a factor in determining which printing method to use. More detailed analysis 
of patterning methods will be discussed in Chapter 2 of this dissertation. 
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Figure 4 Reagent patterning methods. (a), electrospraying is often used to pattern 
lateral flow assays with little loss of enzyme activity. (b), contact printing has the 
advantage of nano-scale resolution printing, however surface energy have to 
modulated to be hydrophilic/hydrophobic. (c), inkjet printing is advantageous 
because there is no contact with the substrates, minimalizing substrate damage. It 
can also pattern a wide range of biological and substrates. It also is 
reprogrammable and can be used for mass production. Microarrays often use this 
kind of technology for printing DNA or proteins. (d), Dip-pen Nanolithography uses 
an AFM tip to transfer liquids via the meniscus at the tip to substrates. This kind of 
patterning can achieve resolution lower than 30nm, however throughput is low with 
this technology. (e), microfluidic channel patterning is simple and low cost, it is 
unique in the sense that multiple washes and reagents can be applied to the same 
surface in a precise way. One common example is patterning antibodies onto 
surfaces. (f), stencils can be used when individual islands of patterns are desired, as 
channel type patterning always require a continuous pattern from inlet to outlet. (g), 
the microfluidic probing method uses hydrodynamic focusing to focus reagents into 
a local region. A continuous flow processing solution run through a pre-wetted 
surface with immersion liquid, additional immersion liquid is applied to focus the 
processing solution. This method produces more uniform patterning, and avoids 
evaporation problems, but consumes more reagents than inkjet printing. (ref: 
Martina Hitzbleck et al. Chem. Soc. Rev., 2013.) 
  
 17 
1.6 Digital amplification platforms 
 
In recent years, there has been a new method of quantifying nucleic acid 
amplification called digital amplification78. This technology can deliver more sensitive 
and robust quantification under environmental variances compared to real-time PCR. 
The mechanism of digital amplification is shown in Figure 579. The key concept of 
digital amplification is to partition one large sample into many nano-liter sized 
samples, and then run PCR reactions in each sub sample until endpoint saturation. 
As the samples are partitioned, each compartment becomes a mini-amplification 
reaction. Each compartment will have either zero or at least one target DNA/RNA. 
Those compartments that have target will amplify, and a final endpoint readout of the 
percentage of positively amplified wells (via fluorescence or colour change) is 
counted. This percentage can be correlated with the initial target concentration, 
similar to what the ct value in real-time PCR elucidates.  
The key advantage of digital amplification is that it is robust against variations in 
kinetics, time, imaging, and analysis techniques, because quantification is end-point, 
not real-time, only the number of compartments that passes threshold are quantified. 
No real-time imagining equipment is needed. Additionally, it delivers much higher 
resolution than PCR systems. Also, the compartmentalization step lowers the 
sample interference from other sources, such as background non target DNA or 
amplification inhibitors, because compartmentalization is increases the target to 
background ratio. 
Figure 5 Concept of digital amplification and superior robustness than real-time 
PCR. (a) Digital amplification works by partitioning samples into small volumes and 
conducting end point detection. (b)  and (c), since digital amplification is end-point 
detection, even though there are kinetic or time variances, the final number of 
positive wells will not vary. (d) imaging and analysis variance also has less effect on 
quantification results. (ref: David A. Selck, et al. Analytical chemistry, 2013.) 
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Previously there have been examples80 of digital amplification for SNP detection, 
copy variance detection, single cell population detection, single cell mRNA 
expression, rare variant detection, methylation-specific amplification, and gene 
expression analysis. There has also been point-of-care assays such as the 
SlipChip81, degas LAMP82, and Self-priming chip83.     
Recently there has also been interesting applications for the detection of other 
molecules than nucleic acids, such as single molecule ELISA84  (Figure 6) and 
single molecule detection of bacteria85 (Figure 7). 
Common platforms of digital PCR can be found in Table 1880. There are two main 
categories, droplet based systems, and microfluidic chambers86. Droplet systems 
have the advantage of producing very large numbers of droplets for high sensitivity; 
while microfluidic chambers are easier to adopt for point-of-care settings, and can 
achieve larger compartment sizes for tuning the detection dynamic range. However, 
one thing to note is that most bench-top systems are still too costly for point-of-care 
applications, costing from $80k~$250k. Most systems need lots of peripherals such 
as pumps, control systems, electricity, and they also need considerable manual 
input. For the future, is essential to build systems that integrate all functions into one 
chip realizing lab-on-chip, rather than chip-in-lab setups. 
 
Figure 6 Single molecule digital ELISA. ~10-19 M level sensitivity was achieved, 
which is roughly 4 orders more sensitive then conventional ELISA.  Antigens were 
captured with magnetic beads and partitioned into 50 fl reaction chambers for digital 
detection.   (ref: David M Rissin, et al. Nature Biotechnology, 2010.) 
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Figure 7 The Integrated Comprehensive Droplet Digital Detection (IC 
3D) platform for single bacteria detection in unprocessed blood. 1 to 
10,000 bacteria per ml can be detected using a DNAzyme-based 
sensor in 1.5~4 hr. DNAzymes are single stranded DNA 
oligonucleotides that are similar to enzymes in the sense that they 
have catalytic activity. In this case, the DNAzyme cleaves the 
ribonulceotide junction (R) when bacteria lysate binds to the 
DNAzyme.  (ref: Dong-Ku Kang, et al. Nature communications, 2014.) 
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Chapter 2. Digital Micro-Patterning of Nucleic Acid 
Amplification Initiator  
 
Abstract 
 
 Patterning of reagents is essential for microfluidic based point-of-care devices that 
need pre-storage or lyophilisation of reagents. However, common techniques such 
as mechanical contact printing is difficult to increase the density of samples, and 
inkjet printing or dispensers require costly specialized equipment and additional 
buffers which may not be compatible with subsequent biological reactions. Here we 
report the digital micro-patterning method that can create high-density micro patterns 
of nucleic acid amplification initiator with common lab equipment in few simple steps. 
By digital degas pumping, automatic reagent spotting was accomplished with 
minimal manual operation (<20 min). High-density patterning (~150 µm footprint) 
was possible by a micro-apex design that concentrates reagents via capillary 
guiding. Without any special solvents or buffers, it was demonstrated to be possible 
to pattern concentrated isothermal amplification initiator (MgOAc) into a microfluidic 
device that contained hundreds of microwells (650 µm diameter) and perform 
isothermal amplification directly. Since only common equipment is necessary, and 
pre-made patterning stencils (or molds of stencils) can be used on-site, this 
technique is ideal for patterning at low resource settings. 
 
 
Introduction 
 
 Micro-patterning of reagents onto chips is a crucial technology for fabricating point-
of-care devices that can be brought into the field. Current common techniques 
include examples such as inkjet printing1, dispensers2, and contact printing3. A 
review of reagent patterning methods has been done by Hitzbleck4 et al. Inkjet 
printing work by using piezoelectric shockwaves to expel liquids through a nozzle 
head. Although this method is rapid, there are several drawbacks with inkjet printing. 
Figure 1 shows some of the common reagent printing technique used.  
 Firstly, the cost for specialized biological compatible inkjet printers can be very 
high (e.g. Arrayjet machines can cost more than $70k, each service run cost ~$2k). 
Secondly, the cost of maintenance is high, as the most costly part—the print heads, 
can be easily damaged, clogged or contaminated with the printed medium. It is also 
risky to attempt to print new materials such as acid, bases, or solvents since these 
materials can damage the print heads. Thirdly, the final shape and footprint depends 
strongly on the hydrophilicity of the substrate and the viscosity of the ink medium. 
Due to uneven evaporation, coffee ring like concentration profiles are often observed 
at the outer boundaries of the printed pattern. Fourthly, to achieve high concentration 
spots, multiple print passes over the same area has to be done. However, each pass 
needs to wait until the previous run is dry before performing the next run if a small 
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footprint is desired. For example, 40 passes (~100 pl/pass) took 8 hours of machine 
time to complete with an Arrajet inkjet printer.  Finally, inkjet printing often requires 
special buffers or solvents to control the viscosity of the printed liquid, which may not 
be compatible with subsequent biological reactions such as nucleic acid 
amplification.   
 Another common technique is printing via robotic dispensers. These machines 
work by dispensing liquid onto substrates via pipetting action through needles or 
pipettes. The main drawback of this method is the lack of resolution to print into 
reagents into microfluidic structures. Smallest print volumes are typically in the range 
of tens or more nanoliters. Also as with inkjet printers, the robotic dispensers can be 
costly and not be part of a list of equipment that laboratories commonly possess.  
 Contact printing5 is also a popular choice. These methods often involve using a 
substrate such as micropatterned PDMS to serve as a stamp to transfer inked 
material onto substrates. Another method is using capillary pins that resemble 
miniaturized fountain pens, and a robotic printer to draw desired patterns on 
substrates. Other methods use a direct writing6,7 action using mechanical tips. 
However, a limitation with these methods is that it is very difficult to produce patterns 
Figure 1 Examples of other common patterning techniques. Ref: (a)14, (b)9, (c)15, 
(d)3, (e)2, (f) referenced from Arrayjet Limited). 
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with high reagent concentration, because a limited volume is transferred during each 
pass. Specialized pin printers are also equipment that is not common to average 
laboratories.  
 Other printing methods such as capillary printing8–10, microfluidic11 networks, 
evaporation12–14, or degas15,16 based printing may be low cost, however, they all 
create continuous patterns defined by the fluidic channels. To our best knowledge, 
there have yet been examples demonstrating patterning of unconnected, discrete 
digitized islands of reagents via these techniques.  
 In this chapter, a new printing method termed “digital micro-patterning” is reported 
(Fig.2). The key advantage to this method is that it enables production of digitized 
    Method 
 
 
Attributes 
Evaporatio
n Capillary Degas 
Micro-
contact 
printing 
Dispensin
g Inkjet 
Digital 
Micro-
patternin
g 
Special 
solvents/ 
buffers 
needed 
initial 
solvent 
layer 
no no yes no yes no 
Digital 
compartm
entalizatio
n 
no no no no no no yes 
Micro-
Apex 
Reagent 
Concentra
tion  
no no no no no no yes 
shape continuous continuous 
contin
uous discrete discrete discrete discrete 
PDMS 
substrate 
patterning 
no yes no yes yes yes yes 
On-site 
patterning difficult easy easy easy difficult difficult easy 
Other 
disadvant
ages 
solvents 
needed  pumps,  
contin
uous 
patter
ns 
cannot 
concentr
ate 
samples
, (pin 
printer)  
high cost, 
footprint 
too large 
high 
cost, 
print 
head 
contami
nation/
damag
e  
NA 
Table 1 Detailed comparison of common patterning techniques.  
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micro-p atterns of highly concentrated reagents into small footprints. Common 
laboratory equipment is used and no specialized solvents are needed. This research 
demonstrates it is possible to pattern magnesium acetate, an amplification initiator 
for isothermal nucleic acid amplification (recombinase polymerase amplification17), 
individually into hundreds of microwells and achieve isothermal amplification within 
these wells.   
 
 
 
 
 
 
Figure 2 Digital micro-patterning of high density reagents for resource-limited 
settings. Digital micro-patterning enables patterning reagents into microfluidic wells. 
The small footprint and high concentration is ideal for subsequent bonding of the 
device. Digital micro-patterning is used to pattern magnesium acetate, an 
amplification initiator, into hundreds of micro-wells (650 µm) diameter each, and run 
isothermal amplification reactions (recombinase polymerase amplification) for 
nucleic acid detection in these wells. Scale bar= 1mm. 
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Methods 
 
Fabrication of PDMS chips 
A cross section of the bi-layer chip construction is shown in Figure 2a. The chips 
tested were fabricated using the standard soft lithography18 process. Briefly, PDMS 
layers containing fluidic channels were made by casting PDMS on a silicon wafer 
that had protruding microfluidic channels created by photo-patterning (OAI Series 
200 Aligner) SU-8 photoresist (Microchem). The digital micro-patterning channels 
were 30 µm high. The wells on the bottom fluidic PDMS chip were 300 µm in height. 
The inlets and outlets of the digital micro-patterning chip were fabricated by punching 
by punchers (Harris Uni-Core, Ted Pella). The outer boundary of the chips were kept 
consistent using a laser cut mold to mold the PDMS into 20x75 mm shapes. All chips 
had a total thickness of 3 mm. PDMS were cured for 4 hours at 60 °C. 
 
Heat treatment of and surface activation of blank PDMS layer 
The blank PDMS layer to be patterned with MgOAc was additionally heat treated 
at 100 °C for at least three days. The heat treatment prevents hydrophobic recovery 
of the plasma treated PDMS surface.  
 
Digital Patterning  
The heat treated blank PDMS was treated with oxygen plasma (PETS Reactive 
Ion Etcher, 100W, 120 mTorr O2, 50 s) to make the surface hydrophilic. After plasma 
treatment, the blank was immediately assembled with the patterning chip and 
vacuumed at 30 mTorr for 10 minutes. Then the outlets of the patterning chips were 
sealed with scotch tape and 2 µl of magnesium acetate solution (MgOAc 1M, Sigma 
Aldrich 63052) was pipetted to each of the inlets immediately (for the fluorescence 
pictures, fluorescein dye was added). After finishing autonomous loading by degas 
pumping (~10 min), the tape at the outlet was removed and excess MgOAc was 
aspirated. The chip was left to air dry in atmosphere for 1 day before peeling. After 
drying, the patterning chip was peeled off in the direction from the base of the leaf 
patterns to the tips of the leaf patterns (from right to left, in the dyed loaded chips 
shown in Fig. 2a). The patterned MgOAc remained on the blank chip.  
 
 
Chip bonding.  
After the blank PDMS chips were patterned with MgOAc, they were bonded to 
the chips that contained the microfluidic wells and channels for the digital plasma 
separation design using UV exposure (UVO cleaner, Jetlight, Model 42) for 3 
minutes. The chips were aligned manually under a stereoscope. After UV bonding, 
the chips were immediately incubated at 60 °C for at least 20 minutes while applying 
~0.5 kg to increase bonding strength. For the reconstitution test, the final assembled 
chips were incubated at -95 kPa overnight and water was loaded into the chip to 
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dissolve the MgOAc.  
 
Quantification  
All fluorescent images and bright field images of zoomed in regions were taken 
with a macroscope (Axiozoom Ems3/SyCoP3, AxioCamMR3 camera, Zeiss) at 
7~20X zoom (PlanNeoFluar Z1.0x objective, Zeiss). I used the 38HE green 
fluorescence filter (Zeiss) for visualizing fluorescein dye. The bit depth was 12 bit, 
images were 692x520 pixels (2,2, binning mode). Acquisition of images and zoomed 
videos were done with Zen (v.2012, Zeiss) software. Imaging was done at room 
temperature. I used NIH imageJ and Zen software to quantify the fluorescence 
intensities, normalize contrast, and crop images. Time-lapse videos of the entire chip 
loading were acquired using the TimeLapse app (xyster.net LLC) using an iPhone 5 
(Apple).   
 
Statistical analysis  
For experimental data, sample sizes are noted in the corresponding figure 
legends. All experimental data are shown as means, and error bars denote plus 
minus one standard deviation. Replicates represent technical replicates. For Figure 
2c, and 2d, the black curve was fitted by a normal distribution curve. I used 
OriginPro (version 9.0, OriginLab) for statistical analysis and scientific graphing.    
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Results 
 
 The location of the magnesium acetate that is patterned is shown in Figure 2 (the 
fluidic functions of the bottom layer will be described in later chapters). The four main 
steps for digital micro-patterning is shown in Figure 3~5. In the first step- digitization 
(Fig. 3), It was able to separate the reagents into discrete islands (~2nl) 
automatically via a fluidic design that uses degas pumping19. Fluid is drawn into the 
microfluidic channels when pre-vacuumed air permeable PDMS material gradually 
sucks out trapped air pockets. The reagents are separated when liquid loading 
finishes and the trailing air gap physically separates each “leaf” pattern. This step 
usually takes less than ~15 minutes after loading.  
 The second step is concentrating the reagents asymmetrically into smaller 
footprints by drying (Fig. 4). The dried patterns have a footprint smaller than 200 µm 
Figure 3 Minimal manual operation with automated digital loading. Amplification 
initiator (MgOAc) can be digitized into discrete samples by degas pumping. In these 
pictures, food-dye was used to visualize the digitization process. (a)~(d) shows the 
timelapse images of reagent loading and digitizing. (e) and (f) shows how degas 
pumping works by slowly sucking liquid when trapped air diffuses into pre-
vacuumed gas permeable silicone (PDMS) material. Digitization occurs when the air 
interface trailing after liquid loading separates patterns into discrete islands. Both 
patterning channels and bottom blanks are made from PDMS.  
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in length. It was able to decrease the footprint by a factor of 2 after drying. For 
visualization, fluorescein or food dye was added for imaging. These results show it 
was possible to reduce the footprint and solidify MgOAc by simply by air-drying in 
atmosphere overnight. Drying under house vacuum further decreased the time 
needed to dry to a few hours. 
 The third step is peeling off the patterning layer (Fig. 5). It was able to 
asymmetrically pattern all of the MgOAc patterns onto the blank PDMS layer by 
Figure 4 Increasing reagent density by micro-apex induced asymmetric patterning. 
In step (b), reagents are further packed into a smaller footprint by capillary guiding 
and air-drying. Fluorescein was added for visualization. Reagents concentrate 
toward the tip asymmetrically via capillary tension. A small reagent footprint 
prevents bonding problems and false positives. False positives can happen if 
contaminating reagents causes unwanted reactions outside the wells. (mean ± s.d., 
n=16). Black scale bars are 250 µm.  
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creating a difference in surface energy. The blank surface was pre-treated with heat 
at 100 °C for at least three days, then exposed to oxygen plasma immediately before 
performing the first step digitization. The plasma treatment made the blank PDMS 
surface hydrophilic and the heat treatment20 prevented the PDMS surface returning 
to a hydrophobic state. Since the top patterning PDMS remained hydrophobic, the 
MgOAc preferentially sticks to the hydrophilic bottom blank surface. In addition, it 
was found that peeling in the direction away from the sharp tips gives better yields. 
The micro-patterned MgOAc showed a very uniform shape and area under the 
microscope (average area was 2.3x104 µm2, and standard deviation was 0.1x3x104 
µm2). No residue of MgOAc was observed in unwanted regions.  
 The final step is assembling the MgOAc patterned layer with the microwell layer 
(Fig. 6). UV bonding and manual alignment was used under a stereoscope for 
Figure 6 Chip bonding and reconstitution. Left figure shows bonded chip with 
microwells. The MgOAc patterned PDMS is flipped, aligned, and bonded on top of 
the bottom half of the iMDx chip. The middile figure shows the result of uniform 
reconstitution after loading the microwells with water. Right figure shows the 
distribution of average intensity of fluorescence from each reconstituted well. n=140. 
Yellow scale bars are 1 mm.  
Figure 5 After peeling patterning stencil layer off. Left figure shows bright field 
image of patterns, no residue is observed at undesired regions. Middle figure shows 
fluorescence image. Right figure shows the results of area distribution. n=140. In 
stepd (d), the MgOAc patterned PDMS is flipped, aligned, and bonded on top of the 
bottom half of the iMDx chip. n=140. Black scale is 250 µm. Yellow scale bar is 1 
mm.  
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bonding. The reduced footprint of the MgOAc prevented the patterns overlapping 
with the bonding areas, thus leaks were avoided. The patterning channels were 
designed to not have any overlaps with the fluidic channels, therefor even if there 
were any residue outside of the desired patterning areas, it would not come in 
contact with the fluidic channels (Fig. 7). After bonding, the reconstitution uniformity 
was tested by loading water into the patterned microwells using degas loading. The 
reconstituted fluorescence intensity distribution was more spread than after the 
concentrated MgOAc after the drying step, but still within tolerable ranges as 
subsequence RPA reactions were still viable. This may be caused from degradation 
of the fluorescein during the UV bonding step. The results for the RPA isothermal 
tests will be shown in the following chapters.     
 
  
Figure 7 Alignment of the patterned reagents and iMDx chip. The blue layer 
represents the fluidic design for the patterning layer. The red layer represents the 
fluidic design for the bottom of the iMDx chip. Note that the patterning layer never has 
overlaps with fluidic channels in the iMDx layer. The patterning layer only routes 
through the vacuum lines of the iMDx chip, this further decreases the risk for residue 
contamination of reagents in the main channel.  
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Discussion  
 
 This project was initially developed because there were no biological grade inkjet 
printers, dispensers, or contact printing robots available in the lab to print micro-
patterns of reagents into microfluidic devices. It was necessary to brainstorm 
methods to make these micropatterns with simple steps and current available lab 
infrastructure. The method developed—digital micro-patterning—requires only 
common lab equipment such as a vacuum source and UV light source. The oxygen 
plasma machine is optional and only needed to render hydrophobic substrates such 
as PDMS to a hydrophilic surface, if the substrate is inherently hydrophilic (e.g. 
glass), then plasma is not required. Due to the low requirements of infrastructure, 
digital micro-patterning can be easily performed in any lab that has these equipment. 
The patterning PDMS molds containing microfluidic patterns can be fabricated by 
facilities that have lithography capability and sent to the laboratories mentioned 
above for in-house PDMS replication molding. Thus, this technique is well suited for 
low resource settings for micro-patterning of highly concentrated reagents.    
 Another merit of this technique is that unlike inkjet printers that require addition of 
viscosity/evaporation modulation buffers, digital micro-patterning does not require 
any special solvents. That means there is less chance for interference with 
downstream assays (e.g. PCR or isothermal amplification). In this system, only  
water was used as the solvent. That being said, this does not limit the system for 
testing other types of solvents or materials. A big advantage of this system is that it 
is possible to boldly try new reagents and solvents because each chip costs only a 
few cents of PDMS material, whereas replacing a damaged inkjet print head may 
cost several thousand dollars. 
 Magnesium acetate, an amplification initiator, was needed to be patterned into the 
wells because if it were contaminate any of the main fluidic channels in the final 
assembled chip, isothermal amplification would commence prematurely and cause 
false positive signals. Magnesium acetate starts recombinase polymerase 
amplification reaction because the polymerase needs a certain concentration of 
magnesium ions to be active.  For this reason, it is crucial to have a small footprint 
so that magnesium acetate do not contaminate outside of the microwells. Also a 
small footprint avoids bonding issues because reagents do not interfere with PDMS 
contact during bonding. Finally, a high density of reagents was desired, and this 
method was unique in the sense that it made it possible to pack reagents in a 3D 
block with a very clear and defined footprint. Contact printing cannot achieve this 
kind of 3D stacking, and inkjet printing’s footprint starts to smear out when high 
volume of liquid is printed.  
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Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In summary, this research demonstrates a new technique that can produce dense 
micro patterns of reagents with common laboratory equipment. For the first time, it 
has been shown that reagents can be patterned by degas-based sample digitization, 
and further concentrated asymmetrically into micro-apex structures via capillary 
drying. The major merits of this system are that no special solvents and special 
robotic equipment are needed. A detailed comparison of technologies is shown in 
and Table 1. As a proof of concept, this work demonstrates that it is possible to 
pattern magnesium acetate into hundreds of microfluidic wells. In later chapters, the 
results of isothermal amplification (via recombinase polymerase amplification) will be 
shown. Due to the versatility of this technique, it may be highly valuable for 
patterning of reagents for microfluidic point-of-care devices in the future.  
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Chapter 3. Vacuum Battery for Portable Microfluidic 
Pumping 
 
Abstract 
 
Low cost pumping is essential to enable microfluidic devices functioning in the 
field. However, common techniques such as capillary fibres used in lateral flow 
assays hinder quantitative optical sensing, and previous degas pumping lacks 
robustness. Herein this report presents the vacuum battery system, which is highly 
robust, portable, and can be easily integrated in chips for advanced microfluidic 
function.  Robustness is achieved by pre-storing large amounts of vacuum potential 
in a void chamber, and discharging the vacuum over gas permeable lung-like 
structures to drive flow (~8 times less loading time standard deviation, and faster 
pumping compared to previous degas pumping). Fully portable tubeless pumping 
was possible without any external power sources or control sources (>2 hours 
operational time, 140 µl). To demonstrate advanced fluidic integration potential, this 
pumping method was integrated seamlessly with sample preparation, optical 
readout, and digital amplification modules into a single quantitative nucleic acid 
detection chip. This simple, low cost pumping design provides a promising 
fundamental building block for future portable microfluidic devices. 
 
Introduction 
 
 Low cost, power-free, portable, and controlled microfluidic pumping are critical 
traits needed for next generation disposable point-of-care medical diagnostic chips. 
Ideally, the pumping system should enable disposable chips to perform on-site 
testing, where there may be poor infrastructure (i.e. trained technicians, power 
source, or equipment). Furthermore, the pumping system should provide a platform 
that is compatible with common quantitative analysis techniques that are usually 
done in centralized labs such as the Enzyme-Linked Immunosorbent Assay (ELISA) 
or Polymerase Chain Reaction (PCR). Preferably, the pumping system should also 
have good optical characteristics so various types of optical detection can be utilized. 
Finally, it should be simple and robust enough so it can be operated with minimal or 
no training.  
 Microfluidic pumping is basically a method to drive fluid flow in miniaturized fluidic 
systems. Microfluidic pumping can be divided into two main categories: active or 
passive pumping, depending on whether the pumping uses external power sources. 
There are several extensive reviews1–5 on microfluidic pumping. Active pumping 
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examples include the syringe pumps, peristaltic pumps6–10, membrane based 
pneumatic valves11,12, centrifugal pumps13, electro-wetting on dielectrics 
(EWOD)14,15, electrosmosis16, piezoelectric pumps17,18, and surface acoustic wave 
actuation methods19,20. Typically active pumping systems have more precise flow 
control and generally larger flow volumes compared to passive systems. However, 
the requirement of external power sources, peripheral control systems, or 
mechanical parts makes the devices more bulky, complex, or costly. These barriers 
make active pumping systems far less feasible for low cost disposable point-of-care 
systems.  
 In passive pumping, there are two main types: capillary or degas pumping. These 
two types are termed passive because these systems typically do not require power 
sources or peripheral equipment for pumping, thus they are ideal for low cost point-
of-care assays. For capillary systems, the lateral flow assay (e.g. pregnancy dipstick 
tests) is a prevalent commercial example. These assays use fibrous materials to 
wick bodily fluids in for immunoassays. In academia, researchers also often use 
fibrous materials such as paper21–23 or even threads24 to drive fluid. However, the 
opaque or reflective fibres can obstruct optical path, or cause higher background 
noise in fluorescent detection. These reasons make transmission type optical 
detection, such as fluorescence, phase contrast, and dark-field microscopy difficult to 
perform in paper capillary formats. 
 There is also capillary pumping in plastic formats. Glucose test strips are a very 
common commercial example of this category. These test strips wick blood into a 
plastic slit for electrochemical detection. In academia, others have also developed 
capillary pumping in plastic25, silicone26–28, and silicon29–31 formats. However, since 
capillary force is dependent on geometry, there are intrinsic limitations in design. For 
example, channels cannot be too thick, therefore deep (mm scale) optically clear 
wells with large diameters are not compatible with capillary designs. Flow channels 
also cannot be too wide, as bubbles may be easily trapped. Periodic structures have 
been used to prevent bubbles from being trapped32, but these structures make the 
fluidic regions not flat and are less desirable for optical detection, as they can cause 
excessive scattering; for instance, in dark-field microscopy or total internal reflection 
microscopy. Furthermore, special surface treatment steps are often needed to 
render the surfaces hydrophilic/hydrophobic, and flow speeds are highly sensitive to 
surface tension differences among liquids.   
 Finally, in all capillary formats, it is not possible to have complete dead-end loading 
or post degassing to remove bubbles. Dead-end loading is useful in nucleic acid 
amplification applications as it prevents evaporation. However, dead-end loading 
cannot be done in capillary systems because an outlet vent for air is always 
necessary. Dead-end loading and the removal of bubbles are of critical importance if 
elevated heat processes are involved, such as heat cycling during PCR, since 
bubbles can expand and cause a catastrophic expulsion of the fluids in the device.  
 These drawbacks have been alleviated by the other more recent example of 
passive pumping, which is called degas pumping33; here, fluid flow is driven when air 
pockets diffuse into the surrounding air permeable pre-vacuumed silicone materials, 
such as polydimethylsiloxane (PDMS). It is analogous to a dry sponge soaking in 
water, but instead of water, air is diffused into the vacuumed silicone and draws fluid 
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movement. The main advantages of degas loading are the ability to load dead-end 
chambers, have great optical clarity, and allow for more flexibility in design 
geometries, as deep and wide structures can be loaded without air bubbles. 
However, the main drawback is the lack of flow control, and fast exponential decay 
of flow rate when the device is taken out of vacuum.  
 Since the first demonstration of degas pumping in 2004 by Hosokawa33, numerous 
applications with this kind of pumping have been developed. Such examples include 
various immunoassays34–37, DNA/RNA hybridization assays33,38, bacterial resistance 
assays39, digital DNA amplification assays40,41, PCR assays42, viscosity assays43,44, 
Surface Plasmon Resonance (SPR) assays45, mercury detection assays46, and 
protein crystallization assays47. There also has been shear-free cell loading48 and 
cell patterning49 applications. An approach using a modular plug-and-play method of 
placing vacuumed PDMS blocks in the outlet to drive flow was also 
demonstrated34,50. This research has also demonstrated trench51 or filter52 based 
plasma separation modules with degas pumping for point-of-care devices. Degas 
pumping has been systematically characterized53 and used to pattern biomolecules 
to guide neuron growth54. Additionally, a modification of degas pumping was 
demonstrated by using a thumb-pump55 to create a vacuum and actuate flow across 
a diffusion barrier instead of pre-storing vacuum as in degas pumping. Another 
recent example from these experiments shows one-step integration of sample 
preparation with digital isothermal amplification of DNA56. 
 This report presents a new “Vacuum Battery System” design, which is the first 
design to use voids to pre-store vacuum potential and gradually discharge vacuum 
via air diffusion through alveoli-like structures to drive flow. Its main advantages over 
conventional degas pumping is that it provides more extended (~2 hrs) and reliable 
flow (~8 times less standard deviation in loading time). Loading speed can be easily 
tuned and enhanced up to 10 times by varying the diffusion area of vacuum lungs or 
changing the size of the vacuum void. This pumping mechanism can load at least 
140 µl of liquid, and compartmentalize liquids into hundreds of dead-end wells for 
digital amplification or multiplexed assay applications. Since vacuum batteries can 
be easily integrated into optically clear microfluidic circuits while leaving design 
flexibility for different geometry, this platform is very valuable for controlled pumping 
in low cost power-free handheld devices. It would be particularly useful in point-of-
care diagnostics as this system is robust and requires no technical skill or extra 
peripheral equipment/power sources for operation. A detailed comparison with 
previous technologies is described in Table 1.  
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 active systems capillary 
Loading 
conventional 
degas flow33 
µSIP55 Vacuum Battery 
System 
examples syringe pumps, 
quake pumps 
pregnancy test 
strips 
SIMBAS51 
system 
Microfluidic 
Solution 
Isolated 
Pumping 
this work 
mechanism external power 
source 
wicking by 
capillary action 
degas through 
permeable 
materials 
degas through 
membrane 
void space stores 
vacuum and degas 
through lung like 
structures 
portability difficult yes yes yes yes 
cost high low low low low 
optical 
properties 
NA fibers are 
opaque or cause 
autofluorescence 
transparent transparent transparent 
flow control excellent superior than 
degas 
flow has fast 
exponential 
decay 
depends on 
thumb pumping 
5 times longer 
decay time 
constant than 
degas flow 
flow speed nl~ml/min µl~ml/min ~µl/min ~nl/min 10 times faster than 
degas, also faster 
than µSIP. 
(nl~µl/min) 
dead end 
loading 
no no yes yes yes 
loading 
volume 
not limited µl-ml nl-µl nl-µl nl-ml 
operation 
time 
not limited secs~mins mins depends on 
thumb pumping 
hours 
geometrical 
constraints 
NA no deep height 
channels 
none none none 
surface 
treatment 
none need to be 
hydrophillic 
none none none 
equipment/ 
power free 
no yes yes need thumb 
pressing 
none 
construction complex with 
peripherals 
simple simple extra valve and 
thumb pump 
needed. 
simple 
Table 1 Pumping technology comparisons. Red labels highlight the 
disadvantages compared to this work.   
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Mechanism of the vacuum battery system  
 
The vacuum battery system is physically separated from the fluid lines 
 The actual chip design using the vacuum battery system is depicted in Figure 1. 
The comparison with conventional degas pumping is in Figure 2. Basic vacuum 
battery is defined to include a “vacuum battery” and “vacuum lung” component with 
an optional waste reservoir (Fig. 2 bottom). The vacuum battery and vacuum lung 
components are connected to each other, but not physically connected to the fluid 
lines. The vacuum battery void component is simply a punched void volume that 
stores vacuum potential and is connected to the vacuum lungs. The “vacuum lungs” 
component mimics lung alveoli gas exchange by allowing air to diffuse through thin 
gas permeable silicone (PDMS) walls across from the fluid lines into the vacuum 
battery. It is important to note that the vacuum battery system is not connected to 
fluid lines as vacuum would be instantly lost once the device is taken out of a 
vacuum environment if it was connected. Instead, gas diffusion is controlled across 
air permeable silicone material by design to regulate flow properties. These two 
components—the vacuum battery and the vacuum lungs—greatly improve the 
pumping characteristics compared to conventional bulk degas pumping in terms of 
robustness, speed, and operation time. ` 
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Figure 1 The low cost integrated vacuum battery system designed for portable 
equipment-free pumping. The above chip was loaded with food dye to highlight 
the microfluidic design. Red color shows where the fluid flows. Blue color shows 
where the main vacuum battery and the vacuum lung structures are. Green 
color shows where the vacuum lines connect to the auxiliary battery to assist 
micro-well loading. Compared with conventional degas flow, the merits are 
outlined in the boxes below.   
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Figure 2 Mechanism of controlled pumping by the vacuum battery system. 
The top schematic shows the side view comparison with conventional bulk 
degas pumping. The vacuum battery system pumps fluid by slowly releasing 
stored vacuum potential via air diffusion over the vacuum lung structures. This 
system is able to deliver more stable and faster flow, over a longer duration of 
time because more vacuum potential can be stored in the void battery space. 
The bottom schematic shows a top view of the basic unit of the vacuum 
battery system. Black arrows depict air diffusing across the vacuum lungs. 
Grey arrows depict air diffusing from bulk PDMS. Flow rate can be tuned 
easily by varying the battery size and lung surface area. 
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 There are four main reasons for these improved characteristics; firstly, the vacuum 
battery void can provide more vacuum potential storage than bulk PDMS and 
therefore more air can be outgassed and resulting in more liquid being sucked in. 
Since more vacuum is accumulated, a longer operation time is possible. This is 
analogous to the arranging batteries in parallel to discharge longer. Secondly, since 
the main vacuum potential is stored in the vacuum batteries, instead of the bulk 
PDMS, the system is less susceptible to losing vacuum power from the sides of the 
devices. This contributes to the higher consistency of fluid loading. Thirdly, air no 
longer has to diffuse through bulk PDMS material, but only through a thin PDMS 
wall. This translates into faster and more consistent flow. In conventional bulk degas 
diffusion, there is a characteristic initial sharp exponential drop in flow rate as air 
diffuses into the surface layers of PDMS, but becomes much slower afterwards as 
air takes much longer to diffuse into the bulk material (Fig. 2). More consistent flow 
is possible since vacuum diffuses with a more constant pressure drop across the 
vacuum lung thin PDMS walls as the vacuum battery provides a large capacitance 
for vacuum energy storage. Fourthly, the flow rate can be easily tuned and increased 
by modifying the surface area of the vacuum lung diffusion area or increasing the 
vacuum battery volume. The combined effects of the vacuum battery system plus 
bulk degas pumping also help increase the flow rate. 
 
Charging, storage, and discharging vacuum potential 
 The basic components of the vacuum battery system and operation steps are 
depicted in the bottom of Figure 2. There are three cycles. The first cycle is the 
charging phase, where the device is put in a vacuum environment and the air from 
the vacuum battery slowly diffuses out. Air also degasses out of the bulk PDMS 
material from the sides of the chip. This step is termed the “charging vacuum 
potential” step. In the second step, if long-term storage is needed, the device is 
packed with a vacuum-sealing machine in aluminium pouches. The devices can be 
stored indefinitely and transported easily in these pouches (Fig. 3), which is a 
desirable attribute for point-of-care diagnostic devices. No observable loading speed 
differences were found with devices that were stored in these pouches for up to a 
year. In the last step, the user simply opens the pouch and loads the liquid sample; 
this is termed the “discharging” step. This step is simple and straightforward, so no 
special training is required to perform it.     
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Governing equations 
 A simplified 2-D diffusion model was built with the COMSOL simulation software 
using the convection diffusion equation. The detailed model setup and general 
assumptions are explained in Fig. 4. 
 The air diffusion across from the fluid channels through the PDMS vacuum lungs 
into the vacuum battery space can be described with the convection-diffusion 
equation57: 
!ci
!t ="# (Di"ci )$"# (u
!
ci ) (1)                                                            
Figure 3 Chip operation protocol. (A) After the chips are incubated in 
vacuum overnight, it is sealed in an aluminum pouch with a vacuum sealer. 
It takes only several seconds to seal each pouch. There is a layer of plastic 
laminated on the inside of the aluminum seals, and by heating the seams 
up, it can melt and seal the pouch. (B) Zoom in on the sealed pouch. This 
pouch can be stored indefinitely and transported easily to remote areas. (C) 
The user simply rips the seal open and load samples in. (D) Loading 
samples in. With the vacuum battery system, there is a long loading window 
of 40 minutes (data shown in Fig. 2) for the user to load the chip.  
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Where ci denotes the concentration species of air in the fluid channel, PDMS, or 
vacuum battery. Di is the diffusion constant of air in each regime, and ! is the 
convection velocity vector in the fluid channel and vacuum battery. In the bulk 
PDMS, there is no convection, therefore the equation simplifies into Fick’s second 
law58:  
 
The pressure in the fluid channels and vacuum battery can be found by correlating 
the gas concentration via the ideal gas law: 
 
where P is the pressure, V is the volume, n is number of moles, R is the Avogadro 
number, and T is the temperature. The volume of liquid being sucked in the device is 
the same volume of air that has diffused into the vacuum battery and PDMS. This 
volume can be calculated by integrating the flux of air concentration being degassed 
over time and surface area. Pressure changes against time plots are shown in Fig. 
5.  
  
(2)                                                            !ci
!t = D"
2ci
(3)                                                            P = nV RT = cRT
Figure 4 Simplified 2D simulation model. The vacuum battery system was 
simplified into a 2D model with four regions, from left to right, the fluid channel 
where air is being drawn out, the thin PDMS membrane of the vacuum lungs 
to control diffusion speed, the vacuum battery void space to store vacuum 
potential, and the surrounding bulk PDMS material. The convection-diffusion 
model was used in COMSOL to simulate this setup. Within the PDMS regions, 
no convection was assumed. Air diffuses gradually from the left to right 
regions.  
   
 
 50 
 
 
 
 
Design of microfluidic chip 
 
The main battery and auxiliary well-loading battery for vacuum storage 
     The two vacuum battery systems that are included on the chip (Fig 1) serve 
different purposes. The main vacuum battery system (top void) connects to the 
vacuum lungs, and draws air in from the fluid line via diffusion across the vacuum 
lungs. It pumps the main fluid flow that goes from the inlet into the waste reservoir 
from left to right. The auxiliary well-loading vacuum battery system (bottom void) is 
connected to the vacuum lines adjacent to the dead-end wells; as in the main battery 
system, they are both not physically connected to the fluid channels, they draw air in 
via diffusion across the PDMS wall, and assist in making the dead-end well’s loading 
speed faster. The auxiliary well-loading battery is optional since conventional degas 
pumping can still cause the wells to be loaded, though at a slower speed. For 
experiments, the auxiliary battery has always been kept at a constant size (100 µl), 
while varying the main battery size to characterize its effect on flow.  Though simple, 
the vacuum batteries voids are the key in enabling large vacuum potential storage in 
the devices to drive flow. 
 
Vacuum lung design mimicking alveoli gas diffusion 
Figure 5 Simulated pressure profile of dashed line in Supplementary Fig. 2. As 
time increases, the vacuum battery void space first fills with air, then it gradually 
diffuses into the bulk PDMS. The bulk PDMS degassing follows a characteristic 
exponential decay in pressure.  
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 This experiment mimicked gas exchange of the lung alveoli by designing closely 
staggered fluid channels and vacuum channels in an array where a 300 µm thin 
PDMS membrane separates them (Fig. 1). It is important to note that the fluid and 
vacuum channels do not physically connect with each other as all pressure 
differences is actuated by gas diffusion across the thin PDMS wall. This is similar to 
the concept that of that blood vessels do not connect with the atmospheric 
environment in alveoli, but rely on diffusion for gas exchange.  Both the fluid 
channels and vacuum channels are 300 µm in width and height. One lung pair is 
defined as one pair of fluid channel plus one pair of vacuum channel, having a 10 
mm2 diffusion cross section area. The number of lung pairs, which determines the 
diffusion cross section, is proportional to the flow speed. Air is able to diffuse through 
the permeable PDMS membrane from the fluid channel into the vacuum lungs and 
then into the main vacuum battery, thus sucking the fluid in. The fluid will never cross 
into the vacuum battery system as the fluid channels and vacuum channels are not 
physically connected.  
 
Deep reservoirs for large loading volume and transmission optics 
 In contrast to capillary pumping, the vacuum battery system enables more flexibility 
in the design of geometries. To demonstrate this, a deep reservoir (5 mm diameter, 3 
mm height, Fig. 1) was designed to retain the excess of pumped liquid. This 
reservoir enables large loading volumes of liquid to be continuously pumped in. The 
device can pump in at least 140 µl, and volume can be easily be further increased by 
punching larger waste reservoirs and vacuum batteries. This is possible because the 
vacuum battery significantly adds to the vacuum capacity of the device compared to 
bulk degassing systems. This additional capacity is the driving force that helps 
outgas the remaining air volume.  The reservoir also helps prevent liquid from 
immediately flowing into the vacuum lung area, thus preventing the flow rate to be 
affected prematurely when the liquid covers the surface area for gas diffusion. The 
capacity for large and deep reservoirs is also advantageous for fluorescent or 
transmission type optical detection as the Beer Lambart law can be fully utilized 
since the optical path length is longer. For example, Enzyme-Linked Immunosorbent 
Assays (ELISA), or real-time PCR assay are common examples that use 
transmission type optical detection, which can be benefit from this system.   
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Methods 
 
Fabrication of microfluidic chips  
 The chips tested were fabricated using the standard soft lithography59 process. 
The same design in Fig. 1 was used for all of the experiments. Briefly, a master mold 
with protruding microfluidic channels were created by photo-patterning (OAI Series 
200 Aligner) 300 µm of SU-8 photoresist (Microchem) onto silicon wafers. Then 3 
mm of Polydimethylsiloxane (PDMS, Sylgard 184, Dow Corning) was poured and 
cured over the silicon wafer mold to replicate the microfluidic channels. All chips 
were made to the same size of 25 mm*75 mm by putting a laser cut acrylic cast 
around the silicone mould, which is the same footprint as a standard microscope 
glass slide. The waste reservoir was punched by a 5mm punch. A separate blank 
piece of 3mm PDMS would be bonded on the top side to seal the fluidic layer by 
oxygen plasma bonding by a reactive ion etching machine (PETS Reactive Ion 
Etcher). Finally, transparent pressure sensitive adhesives (MH 90880, Adhesive 
Research) were taped on both the bottom and top surface of the chip to prevent 
excess gas diffusion. New chips were used for each experiment. A cross section of 
the chip construction is shown in Figure 6.     
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Master mold replication 
 To increase the device assembly throughput, the master silicon mold was 
replicated by casting urethane plastic (Smooth-Cast 327, Smooth-on, Inc.) over the 
molded PDMS devices placed in square petri dishes. A thin layer of release agent 
(Ease Release, Smooth-on Inc.) was applied to the surface of the petri dishes to 
prevent urethane from sticking. The PDMS devices and urethane resin were 
degassed before casting, so no air bubbles would be trapped. The first hour of curing 
was done at 4°C to lower viscosity and slow curing of the urethane resin thus further 
avoiding air bubbles. Afterwards, the resin was left to cure at room temperature 
Figure 6 Simple construction of the device. Only two layers of air permeable 
silicone material (PDMS) are needed. These two layers are bonded together by 
exposing UV light to the PDMS. The bottom layer consists of the fluidic 
components; the large waste reservoir and vacuum battery voids were punched 
with punchers. The top piece is a blank PDMS that has been patterned with 
amplification initiator (MgOAc) on the bottom bonding surface. Transparent 
pressure sensitive adhesive is added on the top and bottom to prevent excess 
air diffusion from the top and bottom surfaces of PDMS. Microfluidic channels 
are highlighted with colors to show different functional parts. Red is the blood 
sample; white are empty channels and vacuum lines. The footprint of this device 
is 25*75 mm, which is the same as a standard microscope slide. 
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overnight and removed from the petri dishes. PDMS was poured into the hardened 
urethane molds to make devices. 
 
Fabrication of vacuum battery void 
 The vacuum battery void would be fabricated by simply punching the 3 mm PDMS 
fluidic layer with through holes before bonding the top and bottom PDMS layers. 
Different diameters of punchers (Harris Uni-Core, Ted Pella) would be used to 
fabricate desired vacuum battery volumes. Pressure sensitive adhesive tape used to 
cover the top and bottom sides would seal these battery voids into compartments.  
 
Vacuum charging and storage 
 The devices would be incubated at -95 kPa for 24 hours in a vacuum chamber 
before liquid loading experiments. The devices would be sealed in aluminium 
vacuum packs by a vacuum sealer (V-402, Van der Stahl Scientific) if long-term 
storage was necessary.  
 
Statistical analysis 
For experimental data, sample sizes are noted in the corresponding figure 
legends. Experiments were repeated in the lab at least three times. All experimental 
data are shown as means, and error bars denote plus minus one standard deviation. 
Replicates represent technical replicates. The Shapiro-Wilk test was used for 
normality testing and verified the data was normally distributed. For the Figure 4a 
and Figure 4b, the inset data was fitted with an inverse function y=a+b*(x+c)-1. For 
both cases, Adj. R-Square=0.99, and P<0.01 (ANOVA). For Figure 5a, the data was 
fitted with an exponential function y=a*exp(b*x). Adj. R-Square was found to be 0.99 
(conv. degas), 0.92 (vac batt sys.), 0.93 (inset), and P<0.01 (ANOVA). OriginPro 
(version 9.0, OriginLab) was used for statistical analysis.    
 
Time gap out of vacuum experiments 
 The devices were taken out of the vacuum chamber and 100µl of diluted blue food 
dye (Assorted Food Colors, Safeway) was pipetted to the inlet at set time intervals 
with a dilution ration in water of 1:25 (Fig. 3A). A video time lapse was taken and the 
flow rate was analysed with ImageJ and Aegisub software. Full loading was defined 
when the dye reaches the end of the vacuum lung structures. The no-battery devices 
were pre-degased and had PDMS poured into all the vacuum lines to fill the vacuum 
battery structure, then it was left to cure at room temperature for 2 days. The no-
battery and with-battery fluidic channels were exactly identical, except that the no-
battery device had all of the vacuum lines and battery voids filled with PDMS. For 
each data point, at least three repeats were performed. 
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Vacuum battery and lung surface area experiments 
 200 µl of diluted blue food dye was pre-loaded into PTFE tubes (Microbore PTFE 
Tubing, 0.03” ID, Cole Parmer) that had a steel tubing connector (SC20/15, Instech 
Solomon) connected to one side. The tubing were connected to the inlet of the 
devices at 15 and 5 minutes after taking the devices out of vacuum respectively for 
the vacuum battery and lung surface area experiments. The volume of food dye left 
to be pumped was monitored by taking a time-lapse video. For each data point, at 
least three repeats were performed.  
 
Flow rate vs. time characterization 
 The flow rate was extracted from the derivative of flow volume vs. time. Originpro 
software was used to extract the derivatives and also fit the flow rate with 
exponential decay curves.  
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Results 
 
 The effects of the vacuum battery system on flow rates were compared with 
conventional degas pumping. Parametric studies were performed by varying the 
operation time gaps, volume of vacuum battery, and surface area of the vacuum lung 
pairs. The results show that the vacuum battery system increases reliability of the 
flow, has longer loading windows, has faster loading, and is easy to tune flow.   
 
More reliable, faster pumping, and longer operation time 
 The effect of the time gap between releasing the chip from vacuum and loading 
liquids was tested. The goal is to demonstrate that the vacuum system provides a 
sufficient long window of operation so users can load the samples at reasonable 
times after opening the vacuum seal. Figure 7A shows the experimental setup and 
how “fully loaded” is defined as liquid fills to the end of the vacuum lungs. It also 
shows how “digitization” is defined by the wells mean. Digitization is defined as 
complete when all 224 wells are filled and compartmentalized when the air gap 
comes in. A volume of 100 µl of blue food dye was loaded into the chips at different 
time gaps after the chip was taken out of the vacuum. Figure 7B shows a time-lapse 
comparison of actual loading. The vacuum battery system finished loading at 40 
minutes while the conventional degas pumping system still had significant portions 
that were not loaded. 
 The vacuum battery system was found to be functional for a longer loading time 
gap for up to 40 minutes, whereas conventional degas pumping failed loading 
starting at 30 minutes (Fig. 7C). Even after idling in atmosphere for 40 minutes out of 
the vacuum, this system still remained functional and continued to pump for another 
107 minutes (Fig. 7C). Thus, the conclusion is that this system can pump reliably for 
at least 2 hrs in total. Though the conventional degas pumping method could 
continue to load for longer times (50~200 min, Fig. 7C) after the liquid is loaded into 
the inlet, the more important factor is the length of the initial time gap that the user 
can load liquids in. Also, a longer post-loading pumping time indicates that 
conventional degas pumping is slower. Regardless of the time gap, loading speed 
was found to be much faster in the vacuum battery system (Fig. 7C). For example, 
at 5 minutes after releasing vacuum, the vacuum battery system was 4.5 times faster 
in loading. Furthermore, the vacuum battery system was much more robust, as it 
followed a linear trend nicely while conventional degas had much more variation, 
with r2 values at 0.97 and 0.83, respectively. Finally, this system was found to be 
much more consistent in repeatability. The standard deviation of the loading time of 
the vacuum battery system was ~8 times less in average than conventional 
degassing (Fig. 7D). In characterizing digitization speed of the wells by varying the 
loading time gap (Fig. 8), the vacuum battery system was also found to enhance 
consistency and digitization speed. Compared to conventional degas pumping, the 
vacuum battery system provides faster loading, a significantly more robust system, 
and a longer window for user operation.  
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Figure 7 More reliable flow, faster flow, and longer operation time compared to 
conventional bulk degas pumping. (A) The experimental setup. (B) Time lapse 
images of loading. The front section of dead-end wells was compartmentalized to 
show adaptability for multiplexed reactions. The chips were loaded after being 
exposed to atmosphere for 10 minutes after taking out of vacuum. (C) The effect on 
flow speed by varying the time gap between taking the device out of vacuum and 
loading. The vacuum battery was significantly faster and more consistent. The 
vacuum battery void volume was kept consistent at 100 µl, n=3. (D) A comparison of 
the standard deviation of loading time extracted from (C).  
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Bubble free loading in wide optical windows 
 The possibility of designing wide fluidic channels (3x15 mm, 300 µm height) in this 
device and loading without any bubbles (Fig. 8) was demonstrated. This is difficult to 
perform in capillary or plastic microfluidic systems. In these systems, accidental 
trapping of bubbles is a common problem in wider geometries. It is critical to have 
minimal bubbles in microfluidic systems as they can easily clog channels, or cause 
catastrophic ejection of liquid when heated due to thermal expansion. This is a 
particular problem in PCR assays. The side vacuum lines were observably helpful in 
removing trapped bubbles much faster than regular bulk degassing in these large 
windows (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8 More reliable and faster digitization compared to 
conventional bulk degas pumping. 100 µl of food dye was loaded into the chip. 
Time to digitize of a well is defined when all 224 wells are fully loaded with food 
dye and compartmentalized when the air plug from the inlet passes by. N=3 for 
all data points.  
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Varying vacuum battery void for fine flow tuning 
 Next up to test was the effect of changing vacuum battery size on the flow 
characteristics. Aside from increasing flow reliability and speed, a larger battery 
resulted in a faster flow rate (Fig. 9). However, flow rate saturated after the battery 
was increased to larger then 150 µl. There were not much difference in loading times 
between the 150 µl and 200 µl battery. The simulation results were plotted with 
dashed lines, and agreed well with experimental results that were in dots (Fig. 9, 
inset). The loading time was found to be inversely proportional to the volume of the 
vacuum battery, and reaches saturation as the volume gets larger.  The flow rates 
were turned at finer increments from 9.0~16.7 µl/min. Tuning flow rates was easily 
accomplished by simply punching different diameter sizes for the vacuum void after 
the mold was already fabricated. This kind of post-processing is very convenient 
since the same mold could be used.  
 
 
 
 
Faster Dead-end loading for Digital PCR or multiplexed assays 
 Dead-end loading is especially useful for PCR reactions because it minimizes 
evaporation problems. Also, dead-end wells can be useful in digital PCR60 
Figure 9 Fine tuning by varying the stored vacuum potential by changing vacuum 
battery volume. Time gap out of vacuum=10 min, n=3. The auxiliary vacuum 
battery was kept constant at 100 µl, while the main vacuum battery volume was 
varied.  
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applications, where one PCR reaction is partitioned and compartmentalized into 
multiple smaller volumes of reactions, and each chamber is run until saturation for a 
digital readout. On the other hand, dead-end wells are also useful for multiplexed 
reactions, for example multiple diseases can be screened in different wells. 
However, dead-end wells would not be possible to load with capillary loading, and 
conventional degas pumping is slow. Consequently, this system’s unique advantage 
is exhibited by demonstrating ~2 times faster dead-end loading (Fig. 10) compared 
to conventional degas pumping. The chip was designed with 224 dead-end wells, 
each having a diameter of 650 µm and a height of 300 µm. This translates to 100 nl 
of volume per well. The vacuum battery system enabled an increase in the loading 
speed of these wells. Vacuum channels, which connect to the vacuum battery, are 
adjacent to the dead-end wells. The wells are connected to the fluidic channels. 
They are separated by a 300 µm PDMS membrane (Fig. 1, bottom zoom). All wells 
were loaded and compartmentalized in 12 minutes with the vacuum battery, whereas 
well loading without the vacuum battery took 23 minutes.   
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Varying vacuum lungs for coarse flow tuning 
 Next up for testing was the effect of vacuum lung cross-section area on flow 
characteristics (Fig. 11). Simulation results were plotted with dashed lines, and 
agreed well with experimental results that were in dots (Fig. 11, inset). It was 
discovered that loading time was also inversely proportional to the surface area of 
Figure 10 Faster compartmentalization (digitization) of the dead-end wells with 
larger vacuum batteries. 100 µl of food dye was loaded into the chip. Digitization 
of a well is defined when a well is fully loaded with food dye and 
compartmentalized when the air plug from the inlet passes by. The chip was left 
in atmosphere pressure for 15 minutes before loading. The auxiliary vacuum 
battery was kept at 100 µl while the main battery volume was varied. N=3 for all 
data points.  
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the diffusion cross-section area. It was possible to tune flow rates with a larger range 
from 1.6~18.2 µl/min by adding the number of “lung pairs”. A lung pair is defined as 
one pair of vacuum and fluidic line (Fig. 11, left). The vacuum lungs had a more 
dramatic effect of increasing loading speed up to 10 times compared to chips that did 
not have any vacuum lungs. In order to tune flow rates, the mold has to be 
predesigned with the desired number of lung pairs.  
 
More consistent flow rates with vacuum battery system 
 Adding vacuum batteries and vacuum lungs contributed to more consistent flow 
rates, as the slope of loading was more linear (See insets of Fig. 11, 12). 
Additionally, the vacuum lungs increased not only the loading speed, but also the 
flow stability (Fig. 13). Flow rate followed the characteristic exponential decay over 
time as in conventional degas pumping, however, the flow rate decay could be made 
much slower when there are more lung pairs. The exponential decay time constant 
was increased ~5 times with this prototype. It is anticipated that further optimization 
of the vacuum battery system is possible: adding extra vacuum batteries would allow 
decay time to be constant even longer, while additional secondary degas lungs to 
degas and stabilize the primary vacuum battery.   
Figure 11 Coarse tuning by varying the diffusion surface area by changing the 
number of lung pairs. Time gap out of vacuum=15min, n=3. Channel height is 300 
µm. Dashed lines in inset are simulation results. Solid dots show experimental 
results.   
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Figure 13 More constant flow rates with slower decay with the vacuum battery 
system.  (A) Flow rates decay slower with the vacuum battery system when there 
are more lung pairs. Time gap out of vacuum =15 min. (B) Exponential decay time 
constant is 5 times slower with the vacuum battery system compared to 
conventional degas pumping. Both vacuum batteries were kept constant at 100µl for 
all experiments, n=3. 
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Discussion  
 Herein is presented the new “vacuum battery system” design, the first 
demonstration of pumping via a vacuum void to store vacuum potential for controlled 
microfluidic pumping in conjunction with biomimetic vacuum lungs. With the new 
design, this research makes advancements in four key areas of flow control 
compared to conventional degas pumping. It also demonstrates that this system can 
be adopted for digital amplification assays. (1) It is possible to attain more stable 
flow, with ~8 times less deviation in loading time and up to ~5 times increase of the 
decay time constant for a much slower and stable exponential decay in flow rate. (2) 
This system can perform reliable pumping for up to 2 hours without any external 
power sources or extra peripheral equipment. (3) It is able to increase loading speed 
to up to 10 times, with a large loading capacity of at least 140 µl. (4) The system is 
possible to easily tune flow and increase flow consistency by varying the vacuum 
battery volume or vacuum lung surface area.  
 This research further improves the distinct advantages of existing degas loading 
traits over capillary pumping. Loading a large array of dead-end wells (224 in total) 
without trapping any bubbles was demonstrated at up to twice the speed. These 
dead-end wells can be adopted for future multiplexed assays or digital PCR assays. 
Faster bubble-free loading of large optical windows and deep wells were shown. 
These are useful in transmission type optical detection, but would be challenging for 
capillary systems to perform. The vacuum battery system does not require any 
special surface treatment and has more flexibility for channel geometry design, as it 
does not rely on surface tension or capillary action to drive flow.  
 It is recommended for designers to follow these simple and straightforward steps 
for their own applications: (1) increase the vacuum battery void if longer operation 
time or sample volume is needed. (2) Increase the number of vacuum lung pairs if 
faster flow speed is desired. (3) Increase the waste reservoir volume if larger sample 
volumes are necessary. Further recommended is to conduct rapid prototyping over 
simulations, as empirical results are more accurate and the experiments are 
straightforward to conduct.   
 All pumping components are directly integrated into the device and can be easily 
manufactured by molding. For mass production, PDMS can be replaced by the use 
of injection molding compatible gas permeable elastomers (e.g. liquid silicone, 
TPE61, etc.). The straightforward construction only requires two layers thus it can be 
manufactured at low cost. The current limitations of this system is the eventual drop 
of the flow rate over time, however the vacuum battery system is already significantly 
more stable than conventional degas pumping. It is believed that flow rate can be 
further stabilized by adding second order vacuum battery systems to degas the first 
battery system.     
 
Conclusion 
 In conclusion, compared to conventional degas loading, the vacuum battery 
system provides significantly more reliable flow, longer operational time, faster flow, 
and easy tunablity of flow rates. In addition, it overcomes several limitations of 
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capillary loading. The vacuum battery system is able to load dead-end wells, load 
deep or wide geometries without bubbles, and has excellent transparent optical 
properties. This simple system is easy to operate, can be stored for long term, is 
convenient to transport, and can be operated on-site without any external power 
sources or equipment. This translates into exciting opportunities for applications 
such as performing on-site ELISA, digital PCR, or multiplexed digital nucleic acid 
amplification. For these reasons, the vacuum battery system is an ideal alternative 
platform technology from capillary systems or conventional degas pumping for future 
handheld point-of-care devices. 
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Chapter 4. Digital Plasma Separation for One-step 
Integrated Molecular Diagnostics  
 
Abstract 
Simple, portable, and quantitative, on-site nucleic acid detection is crucial for next 
generation point-of-care diagnostics. However, complex sample preparation and 
costly/bulky equipment such as real-time PCR machines are required for nucleic acid 
assays. Herein this report documents the digital plasma separation module, which 
enables on-site quantitative nucleic acid detection directly from blood in one-step. 
This design facilitates autonomous sample preparation by removing >90% of blood 
cells without hemolysis. Automatic compartmentalization of samples (224 micro-
wells, 100 nl/well) via vacuum battery pumping enables digital nucleic acid 
amplification. Quantitative digital isothermal amplification of nucleic acid directly from 
human blood mixed with reagents was possible in one-step (10~105 copies DNA/µl, 
via recombinase polymerase amplification, ~30 min). Integration of amplification 
initiator pre-patterning, pumping, and plasma separation resulted in a portable, low 
cost diagnostic chip (iMDx) that can perform quantitative nucleic acid detection 
directly from blood samples. 
 
 
Introduction 
 Next generation point-of-care medical diagnostic assays would ideally be low cost, 
portable, simple, fast, and capable of quantitative nucleic acid detection. Current 
commercially available lateral flow assays (e.g. pregnancy test strips) have many of 
these traits, but typically they are neither quantitative nor capable of nucleic acid 
amplification, providing only positive or negative readouts. Nucleic acid based 
detection is superior in sensitivity and selectivity than immunoassays. However, real-
time PCR, the current standard, is not suited for low cost field-testing. This is 
because it typically involves expensive and bulky thermal cyclers that require 
external power sources, several hours of assay time, multiple manual sample 
preparation steps, or trained technicians. The key problems for on-site nucleic acid 
tests are (1) lack of integrated sample preparation mechanisms, (2) lack of low cost 
quantification methods, and (3) lack of robust portable pumping systems that can 
allow complex microfluidic actuation without external equipment/power sources. 
 New state-of-art commercial real-time PCR1 machines (e.g. GeneXpert, Cepheid) 
have shown robotic automation for sample preparation, solving problem (1). 
However these systems still remain costly, have long assay times, and require 
external power sources, leaving problem (2) unsolved. On the other hand, new 
nucleic acid amplification technologies, such as isothermal amplification1 and digital 
PCR2, can help solve problem (2). Isothermal amplification does not require a 
thermal cycler because all amplification processes are performed via isothermal 
enzyme reactions, thus simplifying the equipment requirements. Digital 
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amplification’s advantage is that it utilizes end-point detection, so no real time 
imaging equipment is necessary. It is also much more robust3 than PCR, as 
environmental variations in temperature, kinetics, time, and imaging have less effect 
on end-point quantification. Digital amplification works by compartmentalizing one 
sample into many individual miniature PCR reactions and amplifying. Then, by 
counting the endpoint number of positive compartments fluorescing, one can 
determine the original template concentration. Previously, sample 
compartmentalization for digital amplification has been conducted via droplet 
microfluidics4, or microfluidic wells5–7; however these techniques mentioned above 
do not address problem (1) as they do not integrate on-chip sample preparation.  
 Addressing problem (1) in the context of working with whole blood samples 
presents many obstacles. Newer polymerases such as the isothermal recombinase 
polymerase can amplify nucleic acid directly in complex solutions such as blood 
plasma8, thus traditional phase separation or spin column purification can be 
bypassed. However, the protocol for blood cell removal must not cause hemolysis in 
the sample. Hemolyzed red blood cells releases hemoglobin, which can disrupt ion 
concentration via chelation, and inhibit polymerase activity9. Also, the opaqueness of 
blood cells also interferes with optical readout. Standard techniques for blood cell 
removal such as centrifugation are difficult to miniaturize. Other membrane or 
mechanical filter10 methods are popular, but they often clog or cause hemolysis. 
Other microfluidic methods11 that utilize hydrodynamic lift force, Zweifach-Fung 
effect12, acoustics, or inertia forces require external power sources, pumps, or  
peripheral control systems. Sedimentation methods13–16 have also been shown, 
however, there has yet to be examples that addresses problems (1), (2), and (3) 
together.   
 The “Integrated Molecular Diagnostics Chip (iMDx)” is presented in this work. It is 
designed to address problems (1), (2), and (3) simultaneously. Two novel 
technologies enable low cost, portable, point-of-care digital nucleic amplification 
directly from blood in one-step. First, the “Digital Plasma Separation” design 
facilitates blood cell removal and simultaneous sample compartmentalization for 
digital amplification. Second, the “Vacuum Battery System” (described in detail in 
Chapter 3), enables significantly more reliable and controlled flow compared to 
previous degas pumping technology, while retaining key benefits including clear 
optics and dead-end loading. In one step, it is possible for end-point quantitative 
digital detection of nucleic acid directly from human whole blood samples in ~30 
minutes with the chip via isothermal Recombinase Polymerase Amplification (RPA). 
This chip is robust and requires no special technical skill. No extra peripheral 
equipment/power sources are needed for portable pumping. This is one of the 
unique examples for next generation nucleic acid testing; it demonstrates a very 
valuable platform technology for future point-of-care medical diagnostic devices.  
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Figure 1 The Digital Plasma Separation design on the Integrated Molecular 
Diagnostics (iMDx) chip for low cost, quantitative, and portable nucleic acid testing. 
(a) The simple operation protocol requires minimal handling and no external pumps 
or power sources. Users simply drop blood mixed with amplification reagents into 
the inlet, then automatic plasma separation and sample compartmentalization is 
performed, the chip is then incubated on a reusable heat pack, and end-point 
isothermal digital amplification of nucleic acid is done. Left side shows a chip filled 
with dye. Right side shows result of digital amplification of 103 copies of Methicillin-
Resistant Staphylococcus Aureus (MRSA) DNA directly from human blood using 
isothermal recombinase polymerase amplification (RPA). Scale bar =2 mm.  (b) 
Schematic of the silicone (polydimethylsiloxane) microfluidic chip that was 
characterized in this study. (c) Top view of auxiliary vacuum lines to assist well 
loading. (d) Side view of the digital plasma separation design that removes blood 
cells via sedimentation, and skims plasma into dead-end wells for digital 
amplification. (e) Shows the result of compartmentalized microwells. Scale bar= 
2mm. 
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Methods 
 
Fabrication of microfluidic chips  
The chips tested were fabricated using the standard soft lithography17 process. 
Briefly, the bottom 3mm PDMS fluidic layer was made by casting PDMS on a silicon 
wafer that had protruding microfluidic channels created by photo-patterned (OAI 
Series 200 Aligner) SU-8 photoresist (Microchem). The main fluid and vacuum 
channels were 300 µm high. Heights of 40, 120, 170, 240, and 300 µm were made 
for the microcliff gap. The waste reservoir was punched by a 5mm punch (Harris Uni-
Core, Ted Pella).  
The vacuum battery void was fabricated by simply punching the bottom 3 mm 
PDMS fluidic layer with through holes. Different diameters of punchers (Harris Uni-
Core, Ted Pella) were used to fabricate desired vacuum battery volumes. A separate 
top blank piece of 3mm PDMS was bonded on the top side to seal the fluidic layer by 
oxygen plasma bonding by a reactive ion etching machine (PETS Reactive Ion 
Etcher, at 100W, 120 mtorr O2, 15 s). All chips were made the same size (25x75 
mm), which is the same footprint as a standard microscope glass slide. For the RPA 
experiments, the blank chips were patterned with MgOAc, and passivated the 
microfluidic surfaces with an anti-biofouling surface treatment so non-specific 
adsorption of protein/DNA would be minimum.  The patterning and passivation 
method will be described in a subsequent publication. Finally, transparent pressure 
sensitive adhesives (MH 90880, Adhesive Research) were taped on both the bottom 
and top surface of the chip to prevent excess gas diffusion and seal off the vacuum 
battery voids. New chips were used for each experiment.  
 
Master mold replication  
To increase the device assembly throughput, the master silicon mold was 
replicated by casting urethane plastic (Smooth-Cast 327, Smooth-on, Inc.) over the 
molded PDMS devices placed in square petri dishes. A thin layer of release agent 
(Ease Release, Smooth-on Inc.) was applied to the surface of the petri dishes to 
prevent urethane from sticking. The PDMS devices and urethane resin were 
degassed before casting, so no air bubbles would be trapped. The first hour of curing 
was done at 4°C to lower viscosity and slow curing of the urethane resin thus further 
avoiding air bubbles. Afterwards, the resin was left to cure at room temperature 
overnight and removed from the petri dishes. PDMS was poured into the hardened 
urethane molds to make devices. 
 
Vacuum charging and storage  
The devices were incubated at -95 kPa for 24 hours in a vacuum chamber before 
liquid loading experiments. The devices could be sealed in aluminium vacuum packs 
by a vacuum sealer (V-402, Van der Stahl Scientific) if long-term storage was 
necessary. 
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Quantification  
All fluorescent images and bright field images of zoomed in regions were taken 
with a macroscope (Axiozoom Ems3/SyCoP3, AxioCamMR3 camera, Zeiss) at 
7~20X zoom (PlanNeoFluar Z1.0x objective, Zeiss). The 38HE green fluorescence 
and 63HE red fluorescence filters (Zeiss) were used for visualizing fluorescein, FAM, 
Toto-1, and Cellmask orange dyes. The bit depth was 12 bit, images were 692x520 
pixels (2,2, binning mode). Acquisition of images and zoomed videos were done with 
Zen (v.2012, Zeiss) software. Imaging was done at room temperature. The NIH 
imageJ and Zen software were used to quantify the fluorescence intensities, 
normalize contrast, crop images, and merge channels. Time-lapse videos of the 
entire chip loading were acquired using the TimeLapse app (xyster.net LLC) using 
an iPhone 5 (Apple).   
 
Statistical analysis  
For experimental data, sample sizes are noted in the corresponding figure 
legends. Experiments were repeated in the lab at least three times. All experimental 
data are shown as means, and error bars denote plus minus one standard deviation. 
Replicates represent technical replicates. The Shapiro-Wilk test for normality testing 
was used to verify that the data was normally distributed.  For Figure 6, Pearson 
Correlation = 0.99, Sig<0.01, two tailed test of significance was used, n=6. For 
Figure 18b, P<0.05, power= 0.999, two tailed t-test. Statistical analysis was done 
using OriginPro (version 9.0, OriginLab).    
 
Digital plasma separation  
For the experiments in Figure 5 and 6, the main channel flow rate was kept at 5 
µl/min by a syringe pump (NE-1600, New Era Pump Systems Inc.), the flow rate into 
the wells was precisely controlled by tuning the vacuum strength to the auxiliary 
battery, a schematic of the setup and correlation of flow rate vs auxiliary battery 
pressure can be found in Figure 2. DNA was fluorescently dyed green (Toto-1 
Iodide, Invitrogen), by mixing DNA (1013 copies/ µl, MRSA) with 400X Toto-1 (diluted 
in 3.5 X TBE) at a ratio of 1:50, and then incubated for 1 hour at 55 °C. Human 
whole blood (HMWBACD, Bioreclaimation) was fluorescently dyed orange (Cellmask 
orange C10045, Invitrogen), by mixing 2X Cellmask dye (diluted in 3.5X TBE) into 
human whole blood (4:9 ratio), and incubated at 37 °C for 20 minutes. The dyed 
blood was centrifuged 5 times (1300 rcf, 5 mins); the supernatant was removed each 
time and replaced with fresh 3.5X TBE buffer. Finally the stained DNA was added to 
the stained blood to make a final mixture that had 20% blood. This mixture was 
loaded into the iMDx chip and the separation efficiency was quantified. Separation 
efficiency was calculated as 1-(blood intensity in well-background intensity)/(blood 
intensity in main channel-backgorund intensity). For data in Figure 6, 5 chips that 
had different microcliff gaps (40,120,170,240,300 µm) were used. Images were 
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taken via a fluorescence macroscope (Axiozoom, Ziess).    
 
 
  
Figure 2 Gradual tuning of microwell filling speed is possible by varying vacuum 
strength. This was the experimental setup for data sets involved with controlled 
flow rates across microcliff gaps. A vacuum source was directly connected to the 
auxiliary battery, applying variable vacuum pressure to characterize the effect on 
microwell filling speed. Flow through the main channel was kept constant using a 
syringe pump. Black dots denote experimental results. Red curve denotes fitting 
results.  n=5.  
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Hemolysis test  
For the ultrasound treated control, a blood sample (20% human whole blood in 
PBS) was lysed with 120 W 40 Hz ultrasound (GB-2500B, Greenultrsonic) for 90 
minutes. This was then loaded into the chip. For the centrifuge control, the same 
blood sample was centrifuged for 10 minutes at 1300 RCF. Plasma supernatant 
extracted therefrom was loaded into the chip. For the digital plasma separation 
control, the same blood sample was dropped directly into the chips. All chips were of 
the 40 µm microcliff gap, 16 lung pair, 100 µl vacuum battery design and incubated 
at -95 kpa vacuum for 24 hrs before the test. The absorbance inside a microwell was 
measured with a spectrometer (USB 2000, Ocean Optics) mounted to a microscope 
(BX51, Olympus) at 50x zoom. The background was normalized to a chip loaded 
with only PBS.    
     
Isothermal digital amplification  
All DNA (MRSA) detection experiments were done with the RPA EXO kit 
(Twistdx, UK). RNA (HIV-1) experiments were done with the RPA RT EXO kit. 
Sequences for primers, FAM probes, and the template can be found in Table 1. 
These sequences were designed according to the original RPA publication18 and 
ordered through Biosearch Technologies and Integrated DNA Technologies.  
Magnesium acetate was pre-patterned into the wells (described in Chapter 2).  
 For the reaction time experiment (Fig. 18b) with HIV-RNA, 10 µl of human whole 
blood (HMWBACD, Bioreclaimation) was mixed with a RPA mix (RPA RT-EXO 
enzyme pellet, 40 µl of primer/probe mix at 10 µM, 59 µl of rehydration buffer, 2 µl of 
10%BSA, 8 µl of RNAsin, and 2 µl of spiked HIV-1 RNA at 2*105 copies/µl). 100µl of 
blood/RPA mix was added into each chip and incubated at 40°C while fluorescent 
time-lapse images were taken with a macroscope (Axiozoom, Zeiss). n=5. 
 For the DNA quantification experiments (Fig. 18c), 2.5 µl of human whole blood 
was mixed with a RPA mix (RPA EXO enzyme pellet, 1.6µl of primer/probe mix at 
100 uM, 59µl of rehydration buffer, 2µl of 10%BSA, 35µl of water, and 2.5µl of spiked 
MRSA DNA at desired concentration). 100µl of blood/RPA mix was added into each 
chip and incubated at 40°C on instant heat packs (HotSnapz) for 1 hour, then 
endpoint fluorescent images were taken with a macroscope. Contrast of images 
were enhanced using the auto-contrast algorithm in the Zeiss Zen software, and 
positively fluorescent wells above the baseline threshold were counted. n!3. 
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MRSA Forward 
primer (sccI/II) 
CTCAAAGCTAGAACTTTGCTTCACTATAAGTATTC 
 
MRSA Reverse 
Primer (orfX) 
 
CCCAAGGGCAAAGCGACTTTGTATTCGTCATTGG
CGGATCAAACG 
 
MRSA II Probe 
sequence 
TGTTAATTGAACAAGTGTACAGAGCATT-T(FAM)-
A-dSpacer-GA-T(BHQ-1)-TATGCGTGGAG  (ordered 
from Biosearch Technologies) 
 
MRSA II target 
sequence 
TTTAGTTGCAGAAAGAATTTTCTCAAAGCTAGAACT
TTGCTTCACTATAAGTATTCAGTATAAAGAATATTTC
GCTATTATTTACTTGAAATGAAAGACTGCGGAGGCT
AACTATGTCAAAAATCATGAACCTCATTACTTATGATA
AGCTTCTTAAAAACATAACAGCAATTCACATAAACCT
CATATGTTCTGATACATTCAAAATCCCTTTATGAAGC
GGCTGAAAAAACCGCATCATTTATGATATGCTTCTC
CACGCATAATCTTAAATGCTCTGTACACTTGTTCAA
TTAACACAACCCGCATCATTTGATGTGGGAATGTCA
TTTTGCTGAATGATAGTGCGTAGTTACTGCGTTGTA
AGACGTCCTTGTGCAGGCCGTTTGATCCGCCAATG
ACGAATACAAAGTCGCTTTGCCCTTGGGTCATGCG 
 
HIV primers and 
probes 
provided by Twistdx, probes are FAM probes for the 
RPA RT-exo kit. 
HIV RNA 
Seracare, 500405, Purified RNA, HIV-1 Group M, 
Subtype B 
Table 1 Primer, probe, and target sequences used for recombines polymerase 
amplification. Primers and target sequence ordered from Integrated DNA 
Technologies. 
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Results 
 The simple user protocol is shown in Figure 1a. The chip has a simple 
construction of two slabs of polydimethylsiloxane (PDMS). With a small footprint 
similar to glass slides (25x75 mm), this device can be stored indefinitely and 
transported easily in airtight aluminium vacuum seals. 
 
Digital Plasma Separation design and mechanism 
 The Digital Plasma Separation sample preparation platform is designed specifically 
for (1) autonomous plasma separation and (2) autonomous sample 
compartmentalization for digital amplification (Fig. 3).  
 
 
 
 
  
Figure 3 One-step autonomous sample preparation with the digital plasma 
separation design. (a) This design enables simultaneous plasma separation and 
sample compartmentalization for digital isothermal amplification. White dashed 
arrows depict air diffusion across the permeable silicone into the vacuum battery, 
driving the flow. Red S shaped lines in wells depicts target nucleic acid to be 
amplified with isotheral amplification. (b) Shows actual blood samples (mixed with 
RPA reagents) being separated into microwells. Blood cells are opaque and 
plasma is transparent in the wells.  
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Hemolysis free plasma separation by the micro-cliff structure 
 A novel “microcliff” structure facilitates plasma separation into the wells by taking 
advantage of blood cell sedimentation. The microcliff skims plasma near the top of 
the microchannel into the wells. Through Navier–Stokes equations19, the flow field 
was computed. Thereafter, the particle trajectories were simulated by computing the 
gravity force and Stokes drag20 that the blood cells experience. The resulting particle 
trajectories are plotted in Figure 4. Separating the blood cells ensured minimal 
optical obstruction of the fluorescence signal, and avoided polymerase inhibition 
from hemoglobin in red blood cells. Samples mixed with RPA reagents are 
compartmentalized automatically into the micro-wells. The micro-wells are pre-
patterned with magnesium acetate, which initiates the RPA reaction when 
reconstituted. Next generation microfluidic pumping with the “vacuum battery 
system”, described below, drives the microfluidic flow.  
 
 
 
Simulation of particle trajectories 
 
  The COMSOL Multiphysics software was used to simulate the flow profile and 
particle trajectories. The first step was to simulate the fluid flow through the 
microfluidic device. The flow can be described with the Navier-Stokes equations. 
Equation (1) is a vector equation representing conservation of momentum: 
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Supplementary Figure 4 Simulation of blood cell trajectories. Simulations were 
performed with COMSOL software. Flow is coming out perpendicular to this page. 
This figure shows plasma separation with a 40 µm microcliff gap, the top part of 
plasma is skimmed into the wells, while the blood cells sediments in the main 
channel. The main channel flow direction is towards the reader.  
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Where ! is the velocity vector (m/s), ! is the density of fluid (kg/m3), p is the pressure 
(Pa), " is the viscous stress tensor (Pa), and F is the volume force vector (N/m3). 
Equation (2) is the continuity equation and describes conservation of mass: 
 
Assuming incompressible flow and steady state laminar flow (Reynolds number <1), 
no-slip boundary conditions were applied to the walls. The single-phase laminar flow 
module in COMSOL simulated the flow field, assuming that blood was diluted into 
PBS (20%), and != 1004 kg/m3.  
 Next, the flow field results were used to simulate the particle trajectories using the 
Particle Tracing for Fluid Flow module. The forces that the blood cells experience are 
drag and gravity forces. The total force experienced on each particle is the sum of 
drag forces and gravity forces:  
 The drag force on the blood cells can is governed by the following equation:  
 
Where mp is the particle mass (kg), "p is the particle velocity response time (s), ! is 
the fluid velocity derived from the flow results (m/s), and ! is the velocity of the 
particle (m/s). For simplicity, blood cells were approximated as spheres, and were 
assumed to experience Stokes drag, since the Reynolds number <1). Therefore, 
using Stoke’s drag law: 
 
 
Where !p is the particle density (1125 kg/m3), dp is the diameter (6 µm), and µ is the 
dynamic viscosity (0.0016 Pa*s). Gravity forces on the blood cells can be described 
with the following equation: 
 
Where g is the gravitational constant. Gravitation force is the main force that causes 
the blood cells sedimentation and allow for plasma skimming on the top edges of the 
main channels. Finally, the particle momentum can be described with Newton’s 
second law, the rate of change of its momentum is equal to the net force the particle 
experiences: 
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Using these equations, and the previously simulated flow field, the particle 
trajectories were simulated in a time dependent model. This simulation was set to 
release particles at the inlet simultaneously at a given time point.  
 
 
 
Microcliffs for efficient, zero clogging, and hemolysis-free blood cell removal 
 Results show that the microcliff design drastically reduces blood cell entry into the 
wells and no clogging is observed (Fig. 5). More than 95% of blood cells can be 
removed, and separation efficiency increases when the h1 microcliff gap or flow rate 
across cliff is reduced (Fig. 6). The parametric simulation result is shown in dashed 
lines and agrees well with experimental results. Increased concentration of blood 
cells in the microwells of the “without cliff” control was observed; this phenomenon is 
possibly due to inertial effects. The best separation efficiency is achieved with the 40 
µm gap microcliff. There is no red blood cell hemolysis observed; the on-chip 
separated plasma showed indistinguishable quality from centrifuged plasma when 
absorbance was measured (Fig. 7). When blood cells enter the wells, the 
fluorescence signal from dyed DNA can be obstructed significantly (Fig. 8). Smaller 
microcliff gaps also make the separation efficiency much more consistent across the 
chip spatially (Fig. 9). This platform can separate blood cells while retaining 
biomarkers, as selective particle separation is possible according to size. Particles 
larger than 1 µm are separated and particles less than 100 nm are retained in the 
wells (Fig. 10). Plasma separation can be done within 12 minutes, with a total 
volume of ~22 µl plasma  (Fig. 11).  
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Figure 5 Fluorescence images of plasma separation of human blood mixed with 
stained DNA. Blood cells tend to obscure DNA readout if it is not separated. 
Contrast normalized. Scale bar=500 µm. 
Figure 6 Smaller microcliff gaps and lower flow speed can remove >95% of blood 
cells. Dashed lines are simulation results. Solid dots show experimental results. 
(mean ± s.d., Pearson Corr= 0.99, p<0.01, two tail t-test, n=6).  
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Figure 7 No hemolysis was observed using this design. Three chips were loaded 
separately with whole blood samples, ultrasound lysed blood, and plasma from 
centrifuged blood. Absorbance spectrum was taken from microwells in each set.  
Figure 8 DNA signal is obstructed when blood cells are not removed. The 
quantitative results show that smaller microcliff gaps can retain higher DNA signal 
because of better blood cell separation. Flow rate across microcliff was kept at 3 
nl/min. Flow rate in the main channel was 5 µl/min. (mean ± s.d., *not significantly 
different, all other pairs were significantly different with p<0.05, one-way ANOVA 
Sidakholm test, n=6) 
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Figure 9 Smaller microcliff gap designs have much more robustness spatially. 
When the gap size of h1 increases, the separation efficiency in the top wells near 
the inlet have very poor blood separation efficiency, this is because the blood cells 
do not have sufficient time to sediment in the main flow channel and get sucked into 
the wells. On the other hand, there is much less variation among top, middle, and 
bottom well separation efficiencies with a smaller microcliff gap design. (mean ± 
s.d., n=6 for all data points).  
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Figure 10 Selective particle separation according to size. The 40 µm micro-cliff gap 
design was tested to separate different sizes of polystyrene particles. It was found to 
be capable of separating >99% of 6 µm beads (which are similar size to red blood 
cells), while retaining >85% of the 0.1 µm beads (which are similar size to some 
viruses). Beads were polystyrene microspheres diluted in PBS. (a) and (b) show 
actual fluorescence pictures of bead separation results. Dashed yellow circles depict 
where the microwells are located. (c) Shows the histogram results and (d) shows 
the mean. Separation efficiency is defined as 1-(intensity in wells-
background)/(intensity in main flow channel-background). (mean ± s.d., *not 
significantly different, all other pairs were significantly different with each other 
p<0.05, one-way ANOVA Sidakholm test, n=224 for all sets. Scale bar is 650 µm). 
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Figure 11 Total plasma volume separated. There are a total of 224 wells, each 
having a volume of 100 nl, which fills with plasma simultaneously. The flow rate 
into the wells was varied by controlling the negative pressure applied to the 
auxiliary vacuum battery. This data was taken from 40 µm microgap iMDx devices. 
The left figure shows human blood that has been spiked with green stained DNA 
(Toto-1), and the blood cells has been stained with red (Cell mask), -15 kPa was 
applied to the auxiliary vacuum battery. Plasma separation could be finished within 
12 minutes. (mean ± s.d., n=6)  
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Integrated plasma separation and compartmentalization for digital amplification 
 This chip can perform autonomous plasma separation and compartmentalization in 
one-step (Fig. 12). Compartmentalization of samples makes each well an individual 
reaction and enables digital amplification. After loading, the receding air gap 
separates each well automatically and the samples are compartmentalized into 224 
micro-wells (100 nl/well). Automatic loading is done via the vacuum battery system. 
Microcliff gaps smaller than 170 µm compartmentalize with 100% success rate (Fig. 
13).  
 
 
  
Figure 12 Time lapse of human blood cell separation from spiked Methicillin-
Resistant Staphylococcus Aureus (MRSA) DNA without clogging. MRSA DNA was 
dyed with green fluorescence (Toto-1, LifeTechnologies), and human blood cells 
were dyed with red fluorescence (Cellmask orange, LifeTechnologies). Images 
show actual one-step plasma separation, compartmentalization, and retention of 
biomarkers in an automated manner. The unique design prevents clogging, which is 
a common problem with membrane filter based techniques. Clogging does not 
happen, as there are no micro-pore constrictions in any part of the design. Even the 
smallest microgap structure is much larger than blood cells, having a cross sectional 
area of 500 x 40 µm (red blood cells are approximately 6 µm in diameter).  
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Figure 13 More reliable compartmentalization with smaller microcliff gap 
designs. Successful compartmentalization is defined as complete filling and 
retaining of liquids within a microwell after the air gap recedes and separates 
each well. An aliquot of 110 µl of human blood (20% blood in PBS) spiked with 
fluorescein was loaded into chips with different microcliff gap heights (h1). 
(mean ± s.d., *not significantly different (40, 120, and 170 µm), all other pairs 
were significantly different with each other p<0.05, one-way ANOVA Sidakholm 
test, n=224 for all sets). 
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The Vacuum Battery System for robust equipment-free portable microfluidic pumping 
 The vacuum battery system was designed to deliver controlled and complex 
microfluidic flow without any external equipment or power sources. The basic 
vacuum battery system includes a “vacuum battery” and “vacuum lung” component 
with an optional waste reservoir. The “vacuum battery” is simply a punched void 
volume that stores vacuum potential and is connected to the vacuum lungs. The 
“vacuum lungs” mimic lung alveoli gas exchange by allowing air to diffuse through 
thin gas permeable silicone (PDMS) walls into the vacuum battery. More detail on 
the vacuum battery system is described in Chapter 3.  
 
One-step quantitative isothermal digital amplification directly from human whole 
blood samples 
 Recombinase Polymerase Amplification18 (RPA) was chosen because it is much 
more robust in plasma samples than PCR or Loop Mediated Isothermal Amplification 
(LAMP) (Fig. 14). RPA is also one of the fastest isothermal amplification 
technologies, and operates at lower temperatures (works at 25°C, ~39°C optimal). 
Using a fluorophore-quencher molecular probe (TwistAmp® exo Probe) that only 
fluoresces when amplicons with matched sequence are present minimized the 
possibility of false-positive signals. A reusable commercial sodium acetate instant 
heat pack can provide ~40°C heating at the microwells for up to an hour for 
isothermal amplification (Fig. 15). Using Poisson statistics, a simulation of digital 
amplification sensitivity range according to well size was done (Fig. 16). Two 
hundred twenty-four wells of 100 nl each were chosen, because this size allows a 
detection range that is physiologically relevant21.  
 This research demonstrated quantitative digital nucleic acid detection directly from 
human blood samples with this chip. The concept and result of digital amplification2 
is shown on in Figure 18. It is possible to rapidly detect signals of HIV-1 RNA spiked 
in human blood (2*105 copies/µl) within 18 minutes. Quantitative detection of MRSA 
DNA (Methicillin-Resistant Staphylococcus Aureus) from 10~105 copies/µl was 
possible in water (Fig. 17) and also directly from spiked human whole blood (Fig. 18). 
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Figure 14 Recombinase polymerase amplification (RPA) is the more robust against 
plasma samples than loop-mediated isothermal amplification (LAMP) and 
polymerase chain reaction (PCR), but blood cells need to be removed. Off-chip tests 
were performed to determine the robustness of each nucleic acid amplification 
technique. Positive control had templates spiked in water, and negative control had 
no template spiked in water. The best case was demonstrated by RPA in plasma. 
Amplification directly from blood was generally very difficult. RPA also showed an 
extremely fast reaction rate, where the fluorescence signal starts to show up in 4 
minutes.  In addition, RPA showed much higher tolerance and remained functional at 
higher plasma concentrations. LAMP was able to amplify in some blood, but only up 
to 5% and gives false positives. On the other hand, the negative control in RPA never 
gave false positive signals. Due to these reasons, the decision was to use RPA to 
demonstrate the utility of the microfluidic plasma separation platform. The RPA-exo 
kit was used for experiments. Data was collected by a real-time PCR machine (CFX-
96, BioRad).   
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Figure 15 Isothermal heating profile inside the iMDx chip from reusable instant 
head packs. The chip’s thickness (3 mm on both top and bottom PDMS) was 
optimized to achieve ~40°C heating inside the wells for up to one hour at 25°C 
ambient temperature. (a) Shows the simulated temperature profile inside the chip’s 
cross section. (b) A commercial reusable instant heat pack (Hotsnapz, ~$5 each) 
was used. The sodium acetate heat pack can be reused after soaking in boiling 
water for ~10 mins. Heating is caused by the exothermic phase change 
crystallization of super saturated sodium acetate. The digital amplification reactions 
were run by simply putting the chips onto a heat pack for 20~60mins. (c) 
Temperature measured at the wells in the iMDx chip using a thermal couple. The 
heat pack was functional for ~1 hr. n=3, mean ± s.d.. At 40°C, this temperature 
range will also work with other isothermal amplification technologies such as 
NASBA, SMART, SDA, BAD AMP.  
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Figure 16 Simulation of the 
well volume’s effect on 
digital amplification dynamic 
range. Poisson statistics 
were used to estimate the 
effects of well volume on 
sensitivity. A volume of 0.1 
µl per well was chosen 
because it is able to detect 
in the range of physiological 
concentrations of common 
blood born pathogens (eg. 
HIV, MRSA). In these 
calculations, 2.5 µl of 
samples were assumedly 
added to a total volume 100 
µl reaction mix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 Experimental results of on-chip digital quantitative detection of Methicillin-
Resistant Staphylococcus Aureus (MRSA) DNA spiked in water. The same 
procedures of testing in Fig. 6c were followed, except that the matrix was in water 
rather than human blood. The sensitivity was slightly higher as there was less 
interference of the plasma components. This shows that the device has potential to 
be used as a replacement of real-time PCR machines for general quantification of 
DNA concentration or water quality monitoring applications.  
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Figure 18 Quantitative digital amplification of nucleic acid directly from human 
blood. (a) Left side shows the concept of digital amplification. Wells that have at 
least one or more target templates are amplified, while others remain unamplified. 
One can determine the original template concentration by counting the number of 
amplified wells. Isothermal nucleic acid amplification was done with recombinase 
polymerase amplification. Isothermal heating was done via reusable sodium 
acetate heat packs. Right side shows end-point fluorescent images of reactions 
with different starting concentration of Methicillin-Resistant Staphylococcus 
Aureus (MRSA) DNA spiked in human whole blood. (b) The average intensity of 
positive spots increases to a detectable level within 18 minutes (mean ± s.d., 
p<0.05, power= 0.999, two tailed t-test, n=5). In this test HIV-1 RNA spiked in 
human whole blood. (c) Shows the quantification range of the iMDx chip. MRSA 
DNA was spiked into human whole blood for these tests (mean ± s.d., solid line 
fitted with B-spline. n=3).   
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Discussion  
 The goal was to design a microfluidic chip capable of functioning in low resource 
settings such as rural villages in third world countries. The assumption was that there 
would be minimal infrastructure, such as lack of centralized labs, electricity, medical 
personnel, and funds for costly equipment. Therefore, the design rule was to create 
a portable diagnostic device that can be operated in one-step, while maintaining 
complex function and minimum cost. A key goal was to bring forth next generation 
technology that can substitute real-time PCR for on-site rapid nucleic acid 
quantification while maintaining the advantages of lateral flows assays such as 
affordability and portability. The aim was to solve three bottlenecks of nucleic acid 
amplification assays in one chip, namely problem (1): lack of integrated sample 
preparation mechanisms, problem (2): lack of low cost quantification methods, and 
problem (3): lack of robust portable pumping systems that can allow complex 
microfluidic actuation without external equipment/power sources. 
 The solution presented here is the iMDx chip, which has the following key merits 
compared with existing technologies- simplicity and affordability, integrated sample 
preparation, portable next generation pumping, and fast quantitative nucleic acid 
readout. Simplicity and affordability: the iMDx chip is designed for one-step operation 
and no specialized technicians are needed. The disposable chip has a simple two-
layer construction, the materials and reagents cost is less than $10, and can be 
further reduced when mass fabricated. Integrated sample preparation: with the digital 
plasma separation platform, for the first time the possibility of simultaneously 
performing automatic plasma separation (>95% blood cell removal, without 
hemolysis or clogging) and microwell compartmentalization was shown. Portable 
next generation pumping: the vacuum battery system demonstrates 
equipment/power-source free complex microfluidic pumping. Robust and tunable 
loading is possible for up to 2 hrs. Pumping is fully integrated into the small chip 
(6mm*25mm*75mm), and the chip can be stored in vacuum seals, making the chip 
highly portable. Also, since this chip is based on highly transparent material 
(silicone), optical readout is superior compared to fibrous lateral flow assays. Fast 
quantitative nucleic acid readout: It was possible to detect nucleic acids 
quantitatively (10~105 copies/µl) within 18 minutes in incubation using isothermal 
digital amplification (RPA), directly from human blood samples. Consequently, the 
total assay time can be done in ~30 minutes (plasma separation ~10 minutes). This 
is comparable to bench top PCR machine sensitivity, but at a significantly lower cost 
and faster readout. A summary of all merits can be found in Fig. 19. 
 For the next step, the goal is to conduct field trials with larger clinical sizes. 
Another aim is to incorporate microfluidic sample concentration modules to further 
increase the assay sensitivity. Currently used for imaging is a bench top 
macroscope. However, the future goal is to develop a simple low-cost portable 
imaging platform, which can be integrated with smart phones for mobile data 
acquisition and analysis, thereby making it possible for telemedicine applications.      
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Conclusion 
 The iMDx chip not only can provide a solution for low resource settings, but also 
has potential to be adopted in developed countries for point-of-care diagnostics as 
well. For example, this chip is aimed for monitoring HIV viral load both in the field 
and also at home, or it may be used for rapid detection of MRSA infection in 
hospitals. It is also possible to pattern different primers into the wells and perform 
multiplexed detection on pathogens that cause similar symptoms such as ebola, 
dengue, and malaria on the same chip. This chip provides much faster and lower 
cost on-site quantitative nucleic acid detection compared to bench-top real-time PCR 
machines. The versatility of this chip will be very beneficial for the development of 
future point-of-care medical diagnostics.    
 
 
 
 
  
Figure 19 The iMDx chip is designed for low resource point-of-care scenarios. 
Actual device loaded with food dye to highlight microfluidic channels.  
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Chapter 5. Conclusions and Future Direction 
Proposed future research direction 
 
 Existing technologies for molecular diagnostics, including those associated with 
lateral flow assays, real time PCR, and ELISA are impractical for use in remote and low-
resource settings.  These assays are prohibitively expensive, slow, and difficult to 
perform, while providing inadequate singelplex results. The proposal is for the 
development of the Integrated Molecular Diagnostics System 2.0 (iMDx 2.0), a next 
generation platform capable of performing multiplexed nucleic acid quantification, 
protein detection, and CD4+ T cell counting. The plan is to build a portable, low-cost 
system based on the expertise in microfluidics, biomolecular analysis, and optics. This 
system will provide a cornerstone example of integration of upstream sample collection 
and downstream quantitative analysis with a manufacturable sample preparation 
module.  The vision for a simplified user workflow is shown in (Fig. 1). This system 
provides a number of key advances over competing technologies (Table.1). The hope is 
to work towards demonstrating an integrated system that can provide end-to-end blood 
based diagnostics from sample collection to signal readout. Focus the initial efforts on 
diseases such as malaria, HIV, or dengue, the system was designed according to the 
Gates Foundation’s target product profile specifications. It is envisioned that this system 
 Lateral flow 
assay 
Real time PCR 
(Genexpert) 
ELISA RPA on 
Paper* 
Future iMDx 
2.0 
(Berkeley) 
Time per assay 10~20min 1~2hr 3~6hr 15 min 10~20min 
CLIA waived yes yes no no yes 
Cost $5-30/test ~$10/test, 
$17k/machine 
$40-70/test, 
$300-1000/kit 
$4.5/test <$5/test, 
less than 
$200/reader 
Quantitative 
nucleic acid 
detection 
no yes no no yes 
Quantitative 
protein 
detection 
no  no yes no yes 
CD4+T cell count no no no no yes 
Power 
requirement 
no electrical outlet 
with UPS 
electrical 
outlet  
no battery 
Portability yes no no yes yes 
Telemedicene  no possible no no yes 
 
Table 1 Technology Comparison 
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Figure. 1 Proposed Integrated Molecular Diagnostics (iMDx 2.0) System Work Flow. 
(1) The user collects blood with a seventh sense device and clicks it onto the iMDx 
2.0 chip, then automatic sample preparation is initiated. (2) Isothermal amplification 
is used (e.g. RPA) to amplify nucleic acids at 40°C on disposable heat packs. 
Througput can be very high as incubation can be done in parallel. Protein assays 
and CD4+T cell counts will be also be quantified. Chips for HIV and malaria will be 
developed using the same platform technology. It may also be adopted to other 
blood based diseases in the future. (3) A smartphone based optical reader will read 
the fluorescence signal and display the results on a app. (4) The app will send data 
to a cloud to be shared with relevant clinicians. 
will accelerate a paradigm shift in the future of quantitative medicine in remote and low-
resource settings. 
 
*Reference: Rohrman, B. A. & Richards-Kortum, R. R. A paper and plastic device for 
performing recombinase polymerase amplification of HIV DNA. Lab on a Chip 12, 3082 
(2012). 
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Future direction 1: Integrate sample preparation module with 
upstream collection and downstream analysis components 
  
A number of technologies for rapid and selective sample preparation were 
developed during this PhD. The plan is to introduce a number of advanced technologies 
to test and complement the sample preparation module. Both upstream sample 
collection and downstream analytical components will be incorporated into a complete 
diagnostic prototype (Fig. 2). The hope is to partner with Seventh Sense Biosystems for 
simple and pain-free phlebotomy as a front-end sample introduction module.  Further 
developed assays for nucleic acid and protein analysis that meet the strict target 
product profile required by the Gates Foundation is necessary. The plan is to develop 
an integrated platform that leverages upstream and downstream technologies for 
sample diagnostic applications such as HIV and malaria.   
 
Activity 1.1: Sample collection integration  
The expectation is to work together with Seventh Sense Biosystems to standardize 
the inlet/outlet format, so that Seventh Sense’s TAP 100 technology can be integrated 
seamlessly with these sample preparation technologies. TAP 100 technology is capable 
of painlessly collecting 100 microliters of whole blood in one step. The blood volume is 
in the range of iMDx2.0’s requirements. The technologies presented here are an ideal 
strategic match: while Seventh Sense specializes in sample collection, this team 
specializes in microfluidic-based whole blood sample preparation for nucleic acid and 
protein-based assays downstream. Integrating this contained sample collection method 
will allow users to bypass dangerous and painful needle based extraction methods and 
simplify the blood collection process. 
 
Activity 1.2: Develop HIV viral load quantification module   
The wish is to continue these efforts in integrating a HIV viral load chip with the 
previously reported digital plasma separation platform (Fig. 3). The main focus is to test 
clinical HIV samples with this chip and compare that to benchmark technology such as 
real-time PCR. On-chip reagent storage and sample lyophilization will have to be 
addressed to achieve full functionality. The main advantage of this system is the 
possibility to bypass costly real time thermal cyclers since only an endpoint result is 
needed. Speed and ease of use is also greatly reduced due to the integration of sample 
preparation (plasma separation+sample digitization) with digital RPA readout. Previous 
chapters have shown detection of HIV-RNA in whole blood within 30 minutes. 
Optimizing these advantages and integrating this module with upstream sample 
collection and downstream readout modules will be continued.   
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Figure 3 Integration of the digital plasma separation module. The core technology 
has been developed during this PhD research. The goal is to integrate this module 
for quantitative nucleic acid assys into the iMDx 2.0 chip. Digital plasma separation 
platform can perform sample prep and digital readout simutaneously, making it 
possible bypass costly thermal cyclers and simplify assay steps greatly. (A) 
mechanism of plasma skiming. (B) digitization process. (C) iMDx 2.0 with the digital 
plasma separation module.  
 
 
Figure 2 Design of the iMDx 2.0 chip. This chip will be capable of performing 
quantitative nucleic acid and quantitative protien detection, CD4+T cell counting 
modules will also be included. Fluid flow is actuated by the vacuum battery system. 
Additional upgrades in function can be integrated easily since the components are 
designed to be modularized.   
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Activity 1.3: Develop CD4+T cell count module 
Another wish is developing a one-step CD4+T cell counting module based on 
CD4+antibody coated polystyrene bead tagging and cell stacking (Fig. 4). The main 
advance compared to other current methods is that this is designed to perform CD4+T 
cell counting with minimal manual steps and use minimal optical equipment for 
quantification. Currently the standard method for CD4+T cell counting is using flow 
cytometry systems, however, these systems are costly (>$10k), and require bulky 
equipment. Newer manual hemocytometry techniques (e.g. Beckman Coulter Manual 
Count kit), use polystyrene bead labeling, which can greatly reduces the cost; however 
they still require multiple manual steps, a microscope, and extra time for counting cells 
manually. Taking advantange of the already validated off-chip kits, the process will be 
automated with microfluidics. Commercial kits such at the Beckman Coulter CD4+T cell 
count kit will be used to first block CD11+/CD4+ monocytes with 0.5µm anti-CD11+ 
beads. The 0.5µm beads cannot be resolved under a microscope, but blocks the 
subsequent anti-CD4+ 2µm bead attachment. After attaching CD4+2µm beads, RBCs 
will be lysed by acetic acid and the tagged CD4+T cells will be stacked with a 
mechanical filter structure. CD4+T cells will be stacked due to a ~4µm increase of 
diameter from the result of bead tagging. A naked eye or simple fluorescence readout 
can be performed with the proposed reader, eliminating the need of a microscope 
objective. A single reading of the stacked length will also be much faster than counting 
all the beads. This lab has already developed similar cell stacking technologies for 
building artificial livers in other projects. (Fig. 4, B-D), a spin out company from this lab, 
Cellasic, has been created and successfully sold to Millipore based on this technology. 
It is anticipated that this technology will be adapted smoothly for CD4+T cell counting 
purposes in the future.   
 
Reference: Lee, P. J., Hung, P. J. & Lee, L. P. An artificial liver sinusoid with a 
microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnology and 
Bioengineering 97, 1340–1346 (2007). 
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Figure. 4 Proposed CD4+T cell counting module design. (A) The plan is to build 
a cell counting assay based on stacking polystyrene bead tagged CD4+T cells. 
The tagged CD4+T cells will be enlarged by ~4µm in diatmeter and start stacking 
in a microfluidic filter. (B-D), this lab has developed similar technolgies for 
stacking cells to create artificial livers on chip.  
 
 
Activity 1.4: Develop a quantitative protein detection module 
Protein detection is highly desirable to be done in parallel with nucleic acid detection. 
This is because protein and viral load peaks at different phases of infection. A dual 
detection scheme will ensure a short window of detection and minimize false negatives. 
The plan is to develop a next generation quantitative protein assay module by using 
gold nanoparticle scattering. It is possible to achieve single biomolecular (protein) 
detection using gold nanoparticles (GNPs) as labels for the detection of target 
molecules. Due to the resonant Rayleigh scattering of GNP, which has is equivalent to 
that of 106 fluorophores; GNPs allow efficient and bright optical detection. Single 
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biomolecular binding events can be imaged in dark-field measurement using total 
internal reflection based GNP scattering excited by wave-guided light. Therefore, highly 
sensitive assays can be developed using this technique. This method can be used for 
protein detection including interferon gamma for TB, p24 for HIV, pLDH and pGluDH for 
malaria.  
 
 
Activity 1.5: Optimize System Materials and Design for Scalable Manufacturing 
Material selection and optimization for scalable manufacture  
Considering the cost effectiveness and yield, the injection molding technique is well 
suited for the production of diagnostic fluidics. In order to take advantage the vacuum 
battery system, the substrate needs to be porous and thus there is a need to optimize 
injection-molding compatible air permeable materials. The integrated devices for 
manufacturing will be sent out to test their compatibility for mass production. 
 
Scalable reagent patterning and lyophilization  
Proteins such as antibody, polymerase are formulated in aqueous solutions to allow 
ease of use, but several degradation processes may be facilitated by the aqueous 
environment. To obtain the desired stability during storage in point-of-care (POC) 
devices, proteins should be dried to reduce the rate of chemical and physical 
degradation. For this, sugars such as sucrose and trehalose can be used during 
lyophilization and storage in a dried solid. The mechanism of stabilization by these 
sugars during drying has been proposed to occur by producing a glassy matrix to 
restrict mobility and/or acting as a water substitute. This freeze-drying technique will be 
used with sugar molecules to prevent the lyophilization-induced protein unfolding, 
aggregation, and degradation during dehydration.  Lyophilized reagents will be pre-
stored on the device for one-step detection. 
 
Module integration for scalable manufacturing 
In this part, the plain is to integrate all the optimized individual modules into one chip 
as shown in Figure 1. The design will be sent to a manufacturing company for making 
large-scale fabrication of the iMDx2.0 chip. The system design will be iterated and 
optimized with the feedback from field-testing. Chip cost is expected to be controlled 
under $5 at scale. 
 
Investigate manufacturing of optical reader system 
The plan is to make a portable iMDx 2.0 optical reader device (See future direction 
2). After the optimization design for mass production is finalized with 3D printing in the 
Lab, the design will be sent to one suitable company for large-scale production of the 
iMDx 2.0 reader. The cost of the iMDx 2.0 reader device will be controlled within $200. 
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Future direction 2: Develop smartphone optical reader and 
integrate wireless data communication for telemedicine 
 
Activity 2.1: Develop Mobile phone optical chip reader and data communication 
app  
 
The wish is to develop a simple, portable and inexpensive optical module using a 
smartphone, which is designed to enable wide distribution in low resource settings. The 
only equipment users would need is the optical box, assuming they have a smart phone 
already. Fabrication costs of this optical reader is to be contrained within $200 USD. 
The optical module is designed to rapidly record fluorescence and dark-field images. 
The information regarding number of copies of target nucleic acid and HIV CD4+T cell 
count will be based on fluorescence images. On the other hand, to determine the 
resulting GNP-based protein assay, the optical system will take dark-field images as 
well. An App, coined iMDx 2.0, will facilitate images recording, image processing, 
generating the diagnosis report and data communicating with cloud system via Health 
Level Seven (HL7) standards. 
Fluorescence images will be recorded and processed by the iMDx App. For 
observation of GNPs, the sideway illumination was made by an array of white LEDs 
equipped on the wall of the chip camber. The LED arrays will excite the microfluidic chip 
with well-defined angle to generate total internal reflection (TIR) illumination, which 
enables high signal-to-noise ratio of dark-field imaging. The strong scattering from the 
particles will share the same optical path with fluorescence channel and be guided into 
camera as well. After image reordering and processing, the diagnosis results will be 
transferred into the report system (see details in Activity 2.2).  
 
Activity 2.2: Develop App software for wireless data communication 
The iMDx App will also be designed to report the results of point-of-care diagnosis of 
HIV, TB or Malaria patients. First, operators (such as nurses) will create the patients’ 
profiles along with personal information. After scanning the QRcode and loading a chip, 
the iMDx reader will identify test type, based on the barcode, and followed by image 
acquisition. After processing both fluorescence and dark-field images, a program 
algorithm will be able to analyze the results and generate a report. For instance, for a 
HIV test, a report will include infection status (e.g. positive or negative), HIV subtype, 
viral load, number of CD4+T cells and the concentration of p24 antigen. Finally, the data 
will be shared with computer severs in hospitals or organizations (such as the World 
Health Organization, WHO) via Health Level Seven (HL7) standards by a cloud system. 
According to the information, doctors in hospitals will be able to suggest treatments and 
organizations will be able to track specific dieses in certain area.  
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Future direction 3: Conduct Field Tests with iMDx 2.0 
   
A sample preparation module has been designed to specifically meet the constraints 
imposed both by the expected sample matrix (human blood) and by the expected 
testing environment (remote and low-resource setting). Initial laboratory experiments 
with spiked and simulated samples were conducted to confirm sample preparation 
performance.  In this objective, the aim is to conduct clinical tests using diagnostic 
devices integrating the sample preparation module with downstream readout 
components developed both internally and through external collaborations. The plan is 
to work with local and international clinical partners to characterize device performance 
in realistic expected environments. The most significant challenge in this objective will 
be obtaining reproducible results using a range of samples that may vary drastically in 
terms of clinical origin.  Furthermore, the wish is to conduct initial tests with minimally 
trained users, quantifying user-to-user variation.   
 
Activity 3.1: Evaluation of integrated device with human samples  
     Sample materials from the Gates Foundation that simulate clinical samples for 
tuberculosis, HIV, and malaria have already been obtained. Initial tests with these 
samples has begun, and will be continued.  The plan is to identify any modifications that 
may need to be made in order to achieve sensitive, specific, and repeatable results 
using these simulated samples. 
 
Activity 3.2: Evaluation of integrated device with samples from UCSF and international 
collaborators 
     The plan is to test the developed assay with clinical samples obtained from partners 
at UCSF and international sites (e.g. Africa). Further device tests will be conducted with 
minimally trained operators in order to measure assay simplicity and reproducibility.  
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Conclusion  
 
This dissertation describes several components that are useful for point-of-care 
diagnostics. The digital micro-patterning method was developed—unique in the sense 
that it can produce highly concentrated micropatterns of reagents with common lab 
equipment. No special equipment such as inkjet printers, dispensers, or contact pin 
robots are needed. Unlike inkjet printing, no special solvents are necessary. As a proof 
of concept, the possibility of patterning amplification initiation reagents into microwells 
and enabling isothermal amplification within these wells was demonstrated. This simple 
patterning method may be easily adopted for low-resource lab settings.  
Another innovation is a new microfluidic pumping method, termed the vacuum 
battery system. This system allows pumping without any external equipment or power 
sources for up to two hours. It is completely portable and integrated with the microfluidic 
device, requiring no additional cost. Compared to previous degas pumping, the vacuum 
battery system is significantly advanced in terms of robustness, speed, and stability. It is 
also possible to load dead-end channels. The silicone material used has excellent 
optical transparency, therfor ideal for optical readout. This is a major advantage 
compared to opaque fibrous capillary systems. Although very simple in design, the 
vacuum battery system has potential to become a transformative technology for 
portable point-of-care devices and compete with conventional capillary pumping in the 
near future. 
A microfluidic sample preparation module was also demonstrated—the digital 
plasma separation platform—capable of processing whole blood for downstream 
biomolecular detection assays. Integrating the above three mentioned inventions, it was 
possible to perform one-step nucleic acid (NA) detection from whole blood within 30 
minutes on the Integrated Molecular Diagnostics (iMDx) chip.  
For future research, the proposal is to expand goals towards system integration. A 
recommendation is to demonstrate the seamless integration of these sample 
preparation modules with common downstream molecular detection such as protein 
assays and cell-counting assays. Another proposition is to investigate materials and 
processes for scalable manufacturing, iterating through this initial design to align with 
the requirements of a streamlined industrial product.  A further plan is to develop a low-
cost optical reader that leverages smartphone technology for rapid data analysis and 
transmission at the point of need. The ultimate aim is to conduct initial field tests with 
international collaborators in order to validate this device and assay design. 
